Identification

Name
Fentanyl
Accession Number
DB00813  (APRD00347, DB05853, DB06055, DB06220)
Type
Small Molecule
Groups
Approved, Illicit, Investigational, Vet Approved
Description

A potent narcotic analgesic, abuse of which leads to habituation or addiction. It is primarily a mu-opioid agonist. Fentanyl is also used as an adjunct to general anesthetics, and as an anesthetic for induction and maintenance. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1078)

Structure
Thumb
Synonyms
  • 1-Phenethyl-4-(N-phenylpropionamido)piperidine
  • 1-phenethyl-4-N-propionylanilinopiperidine
  • Fentanil
  • Fentanila
  • Fentanilo
  • Fentanyl
  • Fentanyl CII
  • Fentanylum
  • N-(1-phenethyl-4-piperidinyl)-N-phenylpropionamide
  • N-(1-phenethyl-4-piperidyl)propionanilide
  • N-(1-Phenethyl-piperidin-4-yl)-N-phenyl-propionamide
  • N-(1-phenethylpiperidin-4-yl)-N-phenylpropionamide
  • N-phenethyl-4-(N-propionylanilino)piperidine
  • N-phenyl-N-(1-(2-phenylethyl)-4-piperidinyl)propanamide
  • Phentanyl
External IDs
AD 923 / AD-923 / IDS-NF-001 / McN-JR 4263-49 / N02AB03 / R 4263 / R 5240
Product Ingredients
IngredientUNIICASInChI Key
Fentanyl citrateMUN5LYG46H990-73-8IVLVTNPOHDFFCJ-UHFFFAOYSA-N
Fentanyl hydrochloride59H156XY461443-54-5LHCBOXPPRUIAQT-UHFFFAOYSA-N
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
AbstralTablet800 ug/1SublingualProstrakan Pharmaceuticals2011-01-07Not applicableUs
AbstralTablet100 ug/1SublingualGalena Biopharma, Inc.2013-08-08Not applicableUs
AbstralTablet400 mcgSublingualPaladin Labs Inc2011-04-18Not applicableCanada
AbstralTablet100 ug/1SublingualProstrakan Pharmaceuticals2011-01-07Not applicableUs
AbstralTablet400 ug/1SublingualGalena Biopharma, Inc.2013-08-08Not applicableUs
AbstralTablet200 mcgSublingualPaladin Labs Inc2011-04-18Not applicableCanada
AbstralTablet400 ug/1SublingualProstrakan Pharmaceuticals2011-01-07Not applicableUs
AbstralTablet600 mcgSublingualPaladin Labs Inc2011-06-14Not applicableCanada
AbstralTablet200 ug/1SublingualGalena Biopharma, Inc.2013-08-08Not applicableUs
AbstralTablet200 ug/1SublingualProstrakan Pharmaceuticals2011-01-07Not applicableUs
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-fentanyl MatrixPatch75 mcgTransdermalApotex Corporation2009-05-13Not applicableCanada
Apo-fentanyl MatrixPatch50 mcgTransdermalApotex Corporation2009-05-13Not applicableCanada
Apo-fentanyl MatrixPatch100 mcgTransdermalApotex Corporation2009-05-13Not applicableCanada
Apo-fentanyl MatrixPatch12 mcgTransdermalApotex CorporationNot applicableNot applicableCanada
Apo-fentanyl MatrixPatch25 mcgTransdermalApotex Corporation2009-05-13Not applicableCanada
FentanylPatch75 ug/hTransdermalMayne Pharma2017-10-02Not applicableUs
FentanylPatch, extended release50 ug/hTransdermalDirectrx2015-01-01Not applicableUs
FentanylPatch, extended release25 ug/hTransdermalTeva2008-12-222016-03-29Us
FentanylPatch, extended release25 ug/hTransdermalLake Erie Medical Dba Quality Care Produts Llc2013-04-04Not applicableUs
FentanylPatch, extended release25 ug/hTransdermalbryant ranch prepack2013-04-04Not applicableUs
Unapproved/Other Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Fentanyl CitrateInjection, solution10 ug/mLIntravenousCantrell Drug Company2011-07-26Not applicableUs
Fentanyl CitrateInjection, solution50 ug/mLIntravenousCantrell Drug Company2011-10-20Not applicableUs
Fentanyl CitrateInjection, solution20 ug/mLIntravenousCantrell Drug Company2013-01-30Not applicableUs
Fentanyl CitrateInjection, solution50 ug/mLIntravenousCantrell Drug Company2013-03-14Not applicableUs
Fentanyl CitrateInjection, solution25 ug/mLIntravenousCantrell Drug Company2012-10-19Not applicableUs
Fentanyl CitrateInjection, solution5 ug/mLIntravenousCantrell Drug Company2013-11-22Not applicableUs
IonsysPatch40 μg/doseTransdermalJanssen Cilag International Nv2006-01-24Not applicableEu
International/Other Brands
Durogesic (Janssen) / Fentanest (Pfizer) / Nasalfent (Archimedes) / Rapinyl (Gedeon Richter)
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Fentanyl Citrate, Bupivacaine HClFentanyl citrate (2 ug/mL) + Bupivacaine hydrochloride (1.25 mg/mL)Injection, solutionEpiduralCantrell Drug Company2012-08-16Not applicableUs
Fentanyl Citrate, Bupivacaine HClFentanyl citrate (1 ug/mL) + Bupivacaine hydrochloride (1.25 mg/mL)Injection, solutionEpiduralCantrell Drug Company2013-08-12Not applicableUs
Fentanyl Citrate, Bupivacaine HClFentanyl citrate (3 ug/mL) + Bupivacaine hydrochloride (1.25 mg/mL)Injection, solutionEpiduralCantrell Drug Company2013-12-18Not applicableUs
Fentanyl Citrate, Bupivacaine HClFentanyl citrate (2 ug/mL) + Bupivacaine hydrochloride (1 mg/mL)Injection, solutionEpiduralCantrell Drug Company2013-09-09Not applicableUs
Innovar InjFentanyl citrate (.05 mg) + Droperidol (2.5 mg)LiquidIntramuscular; IntravenousJanssen Pharmaceutica, Division Of Janssen Ortho Inc.1982-12-311996-09-10Canada
Categories
UNII
UF599785JZ
CAS number
437-38-7
Weight
Average: 336.4705
Monoisotopic: 336.220163528
Chemical Formula
C22H28N2O
InChI Key
PJMPHNIQZUBGLI-UHFFFAOYSA-N
InChI
InChI=1S/C22H28N2O/c1-2-22(25)24(20-11-7-4-8-12-20)21-14-17-23(18-15-21)16-13-19-9-5-3-6-10-19/h3-12,21H,2,13-18H2,1H3
IUPAC Name
N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]propanamide
SMILES
CCC(=O)N(C1CCN(CCC2=CC=CC=C2)CC1)C1=CC=CC=C1

Pharmacology

Indication

For the treatment of cancer patients with severe pain that breaks through their regular narcotic therapy.

Structured Indications
Pharmacodynamics

Fentanyl is an opioid analgesic. Fentanyl interacts predominately with the opioid mu-receptor but also binds to kappa and delta-type opioid receptors. These mu-binding sites are discretely distributed in the human brain, spinal cord, and other tissues. In clinical settings, Fentanyl exerts its principal pharmacologic effects on the central nervous system. Its primary actions of therapeutic value are analgesia and sedation. Fentanyl may increase the patient's tolerance for pain and decrease the perception of suffering, although the presence of the pain itself may still be recognized. In addition to analgesia, alterations in mood, euphoria and dysphoria, and drowsiness commonly occur. Fentanyl depresses the respiratory centers, depresses the cough reflex, and constricts the pupils.

Mechanism of action

Opiate receptors are coupled with G-protein receptors and function as both positive and negative regulators of synaptic transmission via G-proteins that activate effector proteins. Binding of the opiate stimulates the exchange of GTP for GDP on the G-protein complex. As the effector system is adenylate cyclase and cAMP located at the inner surface of the plasma membrane, opioids decrease intracellular cAMP by inhibiting adenylate cyclase. Subsequently, the release of nociceptive neurotransmitters such as substance P, GABA, dopamine, acetylcholine and noradrenaline is inhibited. Opioids also inhibit the release of vasopressin, somatostatin, insulin and glucagon. Fentanyl's analgesic activity is, most likely, due to its conversion to morphine. Opioids close N-type voltage-operated calcium channels (OP2-receptor agonist) and open calcium-dependent inwardly rectifying potassium channels (OP3 and OP1 receptor agonist). This results in hypopolarization and reduced neuronal excitability.

TargetActionsOrganism
AMu-type opioid receptor
agonist
Human
ADelta-type opioid receptor
agonist
Human
UKappa-type opioid receptor
agonist
Human
Absorption

Bioavailability is 92% following transdermal administration and 50% following buccal administration.

Volume of distribution
  • 3 to 8 L/kg [Surgical Patients]
  • 0.8 to 8 [Hepatically Impaired Patients]
Protein binding

80-85%

Metabolism

Fentanyl is metabolized primarily via human cytochrome P450 3A4 isoenzyme system.

Route of elimination

Fentanyl is metabolized primarily via human cytochrome P450 3A4 isoenzyme system and mostly eliminated in urine. Within 72 hours of IV fentanyl administration, approximately 75% of the dose is excreted in urine, mostly as metabolites with less than 10% representing unchanged drug.

Half life

7 hours (range 3-12)

Clearance
  • 27 – 75 L/h [Surgical Patients receving IV administration]
  • 3 – 80 L/h [Hepatically Impaired Patients receving IV administration]
  • 30 – 78 L/h [Renally Impaired Patients receving IV administration]
Toxicity

Fentanyl has an LD50 of 3.1 milligrams per kilogram in rats, and, 0.03 milligrams per kilogram in monkeys. The LD50 in humans is not known.

Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Fentanyl Action PathwayDrug action
Pharmacogenomic Effects/ADRs
Interacting Gene/EnzymeAllele nameGenotype(s)Defining Change(s)Type(s)DescriptionDetails
Cytochrome P450 3A4CYP3A4*20Not Available1461_1462insAADR InferredPoor drug metabolizer, increased adverse drug effects, risk of potentially fatal respiratory depression.Details
Cytochrome P450 3A4CYP3A4*26Not Available802C>TADR InferredPoor drug metabolizer, increased adverse drug effects, risk of potentially fatal respiratory depression.Details

Interactions

Drug Interactions
DrugInteractionDrug group
2,5-Dimethoxy-4-ethylamphetamine2,5-Dimethoxy-4-ethylamphetamine may increase the analgesic activities of Fentanyl.Experimental, Illicit
3,4-Methylenedioxyamphetamine3,4-Methylenedioxyamphetamine may increase the analgesic activities of Fentanyl.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamine4-Bromo-2,5-dimethoxyamphetamine may increase the analgesic activities of Fentanyl.Experimental, Illicit
7-NitroindazoleThe risk or severity of adverse effects can be increased when Fentanyl is combined with 7-Nitroindazole.Experimental
7,8-Dichloro-1,2,3,4-tetrahydroisoquinolineFentanyl may increase the serotonergic activities of 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline.Experimental
AcebutololThe serum concentration of Acebutolol can be increased when it is combined with Fentanyl.Approved
AcepromazineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Acepromazine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Aceprometazine.Approved
AcetaminophenThe serum concentration of Acetaminophen can be increased when it is combined with Fentanyl.Approved
AcetazolamideThe risk or severity of adverse effects can be increased when Fentanyl is combined with Acetazolamide.Approved, Vet Approved
AcetophenazineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Acetophenazine.Approved
Acetylsalicylic acidThe serum concentration of Acetylsalicylic acid can be increased when it is combined with Fentanyl.Approved, Vet Approved
AclidiniumThe risk or severity of adverse effects can be increased when Aclidinium is combined with Fentanyl.Approved
AdipiplonThe risk or severity of adverse effects can be increased when Fentanyl is combined with Adipiplon.Investigational
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Fentanyl.Approved
AgomelatineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Agomelatine.Approved, Investigational
AlaproclateFentanyl may increase the serotonergic activities of Alaproclate.Experimental
AlcuroniumThe risk or severity of adverse effects can be increased when Alcuronium is combined with Fentanyl.Experimental
AldosteroneThe serum concentration of Aldosterone can be increased when it is combined with Fentanyl.Experimental
AlfaxaloneThe risk or severity of adverse effects can be increased when Fentanyl is combined with Alfaxalone.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Fentanyl.Approved, Illicit
AlimemazineAlimemazine may increase the hypotensive activities of Fentanyl.Approved, Vet Approved
AlitretinoinThe serum concentration of Alitretinoin can be increased when it is combined with Fentanyl.Approved, Investigational
AllopregnanoloneThe risk or severity of adverse effects can be increased when Fentanyl is combined with Allopregnanolone.Investigational
AlmotriptanThe risk or severity of adverse effects can be increased when Fentanyl is combined with Almotriptan.Approved, Investigational
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Fentanyl is combined with Alphacetylmethadol.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Alphaprodine.Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Fentanyl.Approved, Illicit, Investigational
AlprenololFentanyl may increase the bradycardic activities of Alprenolol.Approved, Withdrawn
AlvimopanThe risk or severity of adverse effects can be increased when Fentanyl is combined with Alvimopan.Approved
AmbrisentanThe serum concentration of Ambrisentan can be increased when it is combined with Fentanyl.Approved, Investigational
AmilorideThe risk or severity of adverse effects can be increased when Fentanyl is combined with Amiloride.Approved
AmiodaroneThe serum concentration of Fentanyl can be increased when it is combined with Amiodarone.Approved, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Fentanyl is combined with Amisulpride.Approved, Investigational
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Fentanyl.Approved
Ammonium chlorideAmmonium chloride may increase the excretion rate of Fentanyl which could result in a lower serum level and potentially a reduction in efficacy.Approved, Vet Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Fentanyl is combined with Amobarbital.Approved, Illicit
AmoxapineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Fentanyl.Approved
AmperozideThe risk or severity of adverse effects can be increased when Fentanyl is combined with Amperozide.Experimental
AmphetamineAmphetamine may increase the analgesic activities of Fentanyl.Approved, Illicit
Anisotropine MethylbromideThe risk or severity of adverse effects can be increased when Anisotropine Methylbromide is combined with Fentanyl.Approved
ApixabanThe serum concentration of Apixaban can be increased when it is combined with Fentanyl.Approved
AprepitantThe serum concentration of Fentanyl can be increased when it is combined with Aprepitant.Approved, Investigational
AripiprazoleThe risk or severity of adverse effects can be increased when Fentanyl is combined with Aripiprazole.Approved, Investigational
ArotinololFentanyl may increase the bradycardic activities of Arotinolol.Approved
Arsenic trioxideThe serum concentration of Arsenic trioxide can be increased when it is combined with Fentanyl.Approved, Investigational
ArticaineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Articaine.Approved
AsenapineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Asenapine.Approved
AtazanavirThe serum concentration of Fentanyl can be increased when it is combined with Atazanavir.Approved, Investigational
AtenololThe serum concentration of Atenolol can be increased when it is combined with Fentanyl.Approved
AtomoxetineThe serum concentration of Fentanyl can be increased when it is combined with Atomoxetine.Approved
AtorvastatinThe risk or severity of adverse effects can be increased when Fentanyl is combined with Atorvastatin.Approved
AtracuriumThe risk or severity of adverse effects can be increased when Atracurium is combined with Fentanyl.Experimental
Atracurium besylateThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Fentanyl.Approved
AtropineThe risk or severity of adverse effects can be increased when Atropine is combined with Fentanyl.Approved, Vet Approved
AxitinibThe serum concentration of Axitinib can be increased when it is combined with Fentanyl.Approved, Investigational
AzaperoneThe risk or severity of adverse effects can be increased when Fentanyl is combined with Azaperone.Vet Approved
AzelastineFentanyl may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
AzosemideThe risk or severity of adverse effects can be increased when Fentanyl is combined with Azosemide.Investigational
BaclofenThe risk or severity of adverse effects can be increased when Fentanyl is combined with Baclofen.Approved
BarbitalThe risk or severity of adverse effects can be increased when Fentanyl is combined with Barbital.Illicit
BefunololFentanyl may increase the bradycardic activities of Befunolol.Experimental
BelinostatThe serum concentration of Belinostat can be increased when it is combined with Fentanyl.Approved, Investigational
BenactyzineThe risk or severity of adverse effects can be increased when Benactyzine is combined with Fentanyl.Withdrawn
BendroflumethiazideThe risk or severity of adverse effects can be increased when Fentanyl is combined with Bendroflumethiazide.Approved
BenmoxinFentanyl may increase the serotonergic activities of Benmoxin.Withdrawn
BenperidolThe risk or severity of adverse effects can be increased when Fentanyl is combined with Benperidol.Investigational
BenzatropineThe risk or severity of adverse effects can be increased when Benzatropine is combined with Fentanyl.Approved
BenzocaineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Benzocaine.Approved
BenzphetamineBenzphetamine may increase the analgesic activities of Fentanyl.Approved, Illicit
Benzyl alcoholThe risk or severity of adverse effects can be increased when Fentanyl is combined with Benzyl alcohol.Approved
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Fentanyl.Approved, Vet Approved
BetaxololFentanyl may increase the bradycardic activities of Betaxolol.Approved
BevantololFentanyl may increase the bradycardic activities of Bevantolol.Approved
BifeprunoxThe risk or severity of adverse effects can be increased when Fentanyl is combined with Bifeprunox.Investigational
BiperidenThe risk or severity of adverse effects can be increased when Biperiden is combined with Fentanyl.Approved
BisoprololFentanyl may increase the bradycardic activities of Bisoprolol.Approved
BL-1020BL-1020 may increase the hypotensive activities of Fentanyl.Investigational
BoceprevirThe serum concentration of Fentanyl can be increased when it is combined with Boceprevir.Withdrawn
BopindololFentanyl may increase the bradycardic activities of Bopindolol.Approved
BornaprineThe risk or severity of adverse effects can be increased when Bornaprine is combined with Fentanyl.Experimental
BortezomibThe serum concentration of Fentanyl can be increased when it is combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Fentanyl can be decreased when it is combined with Bosentan.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Fentanyl.Approved
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Fentanyl.Approved
BrexpiprazoleThe risk or severity of adverse effects can be increased when Fentanyl is combined with Brexpiprazole.Approved
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Fentanyl.Approved
BrofaromineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Brofaromine.Experimental
BromazepamThe risk or severity of adverse effects can be increased when Fentanyl is combined with Bromazepam.Approved, Illicit
BromisovalThe risk or severity of adverse effects can be increased when Fentanyl is combined with Bromisoval.Experimental
BromocriptineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Bromocriptine.Approved, Investigational
BromperidolThe risk or severity of adverse effects can be increased when Fentanyl is combined with Bromperidol.Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Brompheniramine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Fentanyl is combined with Brotizolam.Approved, Withdrawn
BucindololFentanyl may increase the bradycardic activities of Bucindolol.Investigational
BufuralolFentanyl may increase the bradycardic activities of Bufuralol.Experimental, Investigational
BumetanideThe risk or severity of adverse effects can be increased when Fentanyl is combined with Bumetanide.Approved
BupivacaineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Bupivacaine.Approved, Investigational
BupranololFentanyl may increase the bradycardic activities of Bupranolol.Approved
BuprenorphineFentanyl may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Fentanyl.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Fentanyl.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Butacaine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Fentanyl is combined with Butalbital.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Fentanyl is combined with Butamben.Approved
ButaperazineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Butaperazine.Experimental
ButethalThe risk or severity of adverse effects can be increased when Fentanyl is combined with Butethal.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Fentanyl.Approved, Illicit, Vet Approved
CabazitaxelThe serum concentration of Cabazitaxel can be increased when it is combined with Fentanyl.Approved
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Fentanyl.Approved
CaffeineThe serum concentration of Caffeine can be increased when it is combined with Fentanyl.Approved
CamptothecinThe serum concentration of Camptothecin can be increased when it is combined with Fentanyl.Experimental
CanagliflozinThe serum concentration of Canagliflozin can be increased when it is combined with Fentanyl.Approved
CanertinibThe risk or severity of adverse effects can be increased when Fentanyl is combined with Canertinib.Investigational
Canrenoic acidThe risk or severity of adverse effects can be increased when Fentanyl is combined with Canrenoic acid.Approved, Withdrawn
CanrenoneThe risk or severity of adverse effects can be increased when Fentanyl is combined with Canrenone.Investigational
CarbamazepineThe serum concentration of Fentanyl can be decreased when it is combined with Carbamazepine.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Carbinoxamine.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Fentanyl is combined with Carfentanil.Illicit, Vet Approved
CarfilzomibThe serum concentration of Carfilzomib can be increased when it is combined with Fentanyl.Approved
CariprazineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Cariprazine.Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Fentanyl is combined with Carisoprodol.Approved
CaroxazoneFentanyl may increase the serotonergic activities of Caroxazone.Withdrawn
CarteololFentanyl may increase the bradycardic activities of Carteolol.Approved
CarvedilolFentanyl may increase the bradycardic activities of Carvedilol.Approved, Investigational
CeliprololFentanyl may increase the bradycardic activities of Celiprolol.Approved, Investigational
CeritinibThe serum concentration of Fentanyl can be increased when it is combined with Ceritinib.Approved
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Fentanyl.Withdrawn
CetirizineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Cetirizine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Fentanyl is combined with Chloral hydrate.Approved, Illicit, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Fentanyl.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Fentanyl is combined with Chlormezanone.Approved, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Chloroprocaine.Approved
ChlorothiazideThe risk or severity of adverse effects can be increased when Fentanyl is combined with Chlorothiazide.Approved, Vet Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Chlorphenamine.Approved
ChlorphenoxamineThe risk or severity of adverse effects can be increased when Chlorphenoxamine is combined with Fentanyl.Withdrawn
ChlorphentermineChlorphentermine may increase the analgesic activities of Fentanyl.Illicit, Withdrawn
ChlorproethazineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Chlorproethazine.Experimental
ChlorpromazineThe serum concentration of Chlorpromazine can be increased when it is combined with Fentanyl.Approved, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Fentanyl is combined with Chlorprothixene.Approved, Withdrawn
ChlorthalidoneThe risk or severity of adverse effects can be increased when Fentanyl is combined with Chlorthalidone.Approved
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Fentanyl is combined with Chlorzoxazone.Approved
CicletanineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Cicletanine.Investigational
CimetidineThe serum concentration of Cimetidine can be increased when it is combined with Fentanyl.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Cinchocaine.Approved, Vet Approved
CiprofloxacinThe serum concentration of Ciprofloxacin can be increased when it is combined with Fentanyl.Approved, Investigational
CirazolineThe serum concentration of Fentanyl can be decreased when it is combined with Cirazoline.Experimental
CisplatinThe serum concentration of Cisplatin can be increased when it is combined with Fentanyl.Approved
CitalopramThe risk or severity of adverse effects can be increased when Citalopram is combined with Fentanyl.Approved
ClarithromycinThe serum concentration of Fentanyl can be increased when it is combined with Clarithromycin.Approved
ClemastineThe serum concentration of Fentanyl can be increased when it is combined with Clemastine.Approved
ClidiniumThe risk or severity of adverse effects can be increased when Fentanyl is combined with Clidinium.Approved
ClobazamThe serum concentration of Clobazam can be increased when it is combined with Fentanyl.Approved, Illicit
ClofenamideThe risk or severity of adverse effects can be increased when Fentanyl is combined with Clofenamide.Experimental
clomethiazoleThe risk or severity of adverse effects can be increased when Fentanyl is combined with clomethiazole.Investigational
ClomifeneThe serum concentration of Clomifene can be increased when it is combined with Fentanyl.Approved, Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Clomipramine.Approved, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Fentanyl is combined with Clonazepam.Approved, Illicit
ClonidineThe serum concentration of Clonidine can be increased when it is combined with Fentanyl.Approved
ClopamideThe risk or severity of adverse effects can be increased when Fentanyl is combined with Clopamide.Experimental
ClopenthixolThe risk or severity of adverse effects can be increased when Fentanyl is combined with Clopenthixol.Experimental
ClopidogrelThe serum concentration of Clopidogrel can be increased when it is combined with Fentanyl.Approved, Nutraceutical
CloranololFentanyl may increase the bradycardic activities of Cloranolol.Experimental
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Fentanyl.Approved, Illicit
ClorexoloneThe risk or severity of adverse effects can be increased when Fentanyl is combined with Clorexolone.Experimental
ClothiapineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Clothiapine.Experimental
ClotrimazoleThe serum concentration of Fentanyl can be increased when it is combined with Clotrimazole.Approved, Vet Approved
ClozapineThe serum concentration of Clozapine can be increased when it is combined with Fentanyl.Approved
CobicistatThe serum concentration of Fentanyl can be increased when it is combined with Cobicistat.Approved
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Fentanyl.Approved
CocaineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Cocaine.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Fentanyl.Approved, Illicit
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Fentanyl.Approved
Conjugated estrogensThe serum concentration of Conjugated estrogens can be increased when it is combined with Fentanyl.Approved
CopanlisibThe serum concentration of Copanlisib can be increased when it is combined with Fentanyl.Approved
CrizotinibThe serum concentration of Fentanyl can be increased when it is combined with Crizotinib.Approved
CyamemazineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Cyamemazine.Approved
CyclizineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Cyclizine.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Cyclobenzaprine.Approved
CyclopenthiazideThe risk or severity of adverse effects can be increased when Fentanyl is combined with Cyclopenthiazide.Experimental
CyclopentolateThe risk or severity of adverse effects can be increased when Cyclopentolate is combined with Fentanyl.Approved
CyclosporineThe serum concentration of Fentanyl can be increased when it is combined with Cyclosporine.Approved, Investigational, Vet Approved
CyclothiazideThe risk or severity of adverse effects can be increased when Fentanyl is combined with Cyclothiazide.Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Cyproheptadine.Approved
Dabigatran etexilateThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Fentanyl.Approved
DabrafenibThe serum concentration of Fentanyl can be decreased when it is combined with Dabrafenib.Approved
DactinomycinThe serum concentration of Dactinomycin can be increased when it is combined with Fentanyl.Approved
DantroleneThe risk or severity of adverse effects can be increased when Fentanyl is combined with Dantrolene.Approved
DapagliflozinThe serum concentration of Dapagliflozin can be increased when it is combined with Fentanyl.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Fentanyl is combined with Dapiprazole.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Fentanyl.Investigational
DarifenacinThe risk or severity of adverse effects can be increased when Darifenacin is combined with Fentanyl.Approved, Investigational
DarunavirThe serum concentration of Fentanyl can be increased when it is combined with Darunavir.Approved
DasabuvirThe serum concentration of Fentanyl can be increased when it is combined with Dasabuvir.Approved
DasatinibThe serum concentration of Fentanyl can be increased when it is combined with Dasatinib.Approved, Investigational
DaunorubicinThe serum concentration of Daunorubicin can be increased when it is combined with Fentanyl.Approved
DebrisoquinThe serum concentration of Debrisoquin can be increased when it is combined with Fentanyl.Approved
DeferasiroxThe serum concentration of Fentanyl can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe serum concentration of Fentanyl can be increased when it is combined with Delavirdine.Approved
DeramciclaneThe risk or severity of adverse effects can be increased when Fentanyl is combined with Deramciclane.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Fentanyl is combined with Desflurane.Approved
DesipramineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Desipramine.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Desloratadine.Approved, Investigational
DesmopressinThe risk or severity of adverse effects can be increased when Fentanyl is combined with Desmopressin.Approved
DesvenlafaxineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Desvenlafaxine.Approved
DetomidineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Detomidine.Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Dexbrompheniramine.Approved
DexetimideThe risk or severity of adverse effects can be increased when Dexetimide is combined with Fentanyl.Withdrawn
DexmedetomidineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Dexmedetomidine.Approved, Vet Approved
DextroamphetamineDextroamphetamine may increase the analgesic activities of Fentanyl.Approved, Illicit
DextromethorphanThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Fentanyl.Approved
DextromoramideThe risk or severity of adverse effects can be increased when Fentanyl is combined with Dextromoramide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Fentanyl is combined with Dextropropoxyphene.Approved, Illicit, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Dezocine.Approved
DiazepamThe serum concentration of Diazepam can be increased when it is combined with Fentanyl.Approved, Illicit, Vet Approved
DicyclomineThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Fentanyl.Approved
Diethyl etherThe risk or severity of adverse effects can be increased when Fentanyl is combined with Diethyl ether.Experimental
DiethylpropionDiethylpropion may increase the analgesic activities of Fentanyl.Approved, Illicit
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be increased when it is combined with Fentanyl.Approved
DifenoxinThe risk or severity of adverse effects can be increased when Fentanyl is combined with Difenoxin.Approved, Illicit
DigitoxinThe serum concentration of Digitoxin can be increased when it is combined with Fentanyl.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Fentanyl.Approved
DihydrocodeineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Dihydrocodeine.Approved, Illicit
DihydroergocornineThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Fentanyl.Approved
DihydroergocristineThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Fentanyl.Experimental
DihydroergocryptineThe risk or severity of adverse effects can be increased when Dihydroergocryptine is combined with Fentanyl.Experimental
DihydroergotamineThe serum concentration of Fentanyl can be increased when it is combined with Dihydroergotamine.Approved
DihydroetorphineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Dihydroetorphine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Dihydromorphine.Experimental, Illicit
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be increased when it is combined with Fentanyl.Illicit
DiltiazemThe serum concentration of Fentanyl can be increased when it is combined with Diltiazem.Approved
DimenhydrinateThe risk or severity of adverse effects can be increased when Fentanyl is combined with Dimenhydrinate.Approved
DiphenhydramineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Diphenhydramine.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Fentanyl is combined with Diphenoxylate.Approved, Illicit
DipyridamoleThe serum concentration of Dipyridamole can be increased when it is combined with Fentanyl.Approved
DixyrazineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Dixyrazine.Experimental
DocetaxelThe serum concentration of Docetaxel can be increased when it is combined with Fentanyl.Approved, Investigational
DolasetronDolasetron may increase the serotonergic activities of Fentanyl.Approved
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Fentanyl.Approved, Investigational, Vet Approved
DoramectinThe risk or severity of adverse effects can be increased when Fentanyl is combined with Doramectin.Vet Approved
DoxepinThe risk or severity of adverse effects can be increased when Fentanyl is combined with Doxepin.Approved
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Fentanyl.Approved, Investigational
DoxycyclineThe serum concentration of Fentanyl can be increased when it is combined with Doxycycline.Approved, Investigational, Vet Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Fentanyl.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Fentanyl is combined with DPDPE.Investigational
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Fentanyl.Approved, Illicit
DronedaroneThe serum concentration of Fentanyl can be increased when it is combined with Dronedarone.Approved
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Fentanyl.Approved, Vet Approved
DrospirenoneThe risk or severity of adverse effects can be increased when Fentanyl is combined with Drospirenone.Approved
DrotebanolThe risk or severity of adverse effects can be increased when Fentanyl is combined with Drotebanol.Experimental, Illicit
DuloxetineThe risk or severity of adverse effects can be increased when Duloxetine is combined with Fentanyl.Approved
DyclonineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Dyclonine.Approved
EcgonineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Ecgonine.Experimental, Illicit
EcopipamThe risk or severity of adverse effects can be increased when Fentanyl is combined with Ecopipam.Investigational
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Fentanyl.Approved
EfonidipineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Efonidipine.Approved
ElbasvirThe serum concentration of Elbasvir can be increased when it is combined with Fentanyl.Approved
EletriptanThe risk or severity of adverse effects can be increased when Eletriptan is combined with Fentanyl.Approved, Investigational
EltanoloneThe risk or severity of adverse effects can be increased when Fentanyl is combined with Eltanolone.Investigational
EluxadolineFentanyl may increase the constipating activities of Eluxadoline.Approved
EmeproniumThe risk or severity of adverse effects can be increased when Emepronium is combined with Fentanyl.Experimental
EnasidenibThe serum concentration of Enasidenib can be increased when it is combined with Fentanyl.Approved
EnfluraneThe risk or severity of adverse effects can be increased when Fentanyl is combined with Enflurane.Approved, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Fentanyl is combined with Entacapone.Approved, Investigational
EnzalutamideThe serum concentration of Fentanyl can be decreased when it is combined with Enzalutamide.Approved
EpanololFentanyl may increase the bradycardic activities of Epanolol.Experimental
EpinastineThe serum concentration of Epinastine can be increased when it is combined with Fentanyl.Approved, Investigational
EplerenoneThe risk or severity of adverse effects can be increased when Fentanyl is combined with Eplerenone.Approved
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Fentanyl is combined with Ergoloid mesylate.Approved
ErgonovineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Ergonovine.Approved
ErgotamineThe serum concentration of Fentanyl can be decreased when it is combined with Ergotamine.Approved
ErlotinibThe serum concentration of Erlotinib can be increased when it is combined with Fentanyl.Approved, Investigational
ErythromycinThe serum concentration of Fentanyl can be increased when it is combined with Erythromycin.Approved, Vet Approved
EscitalopramThe risk or severity of adverse effects can be increased when Fentanyl is combined with Escitalopram.Approved, Investigational
EsmololFentanyl may increase the bradycardic activities of Esmolol.Approved
EstazolamThe risk or severity of adverse effects can be increased when Fentanyl is combined with Estazolam.Approved, Illicit
EstradiolThe serum concentration of Estradiol can be increased when it is combined with Fentanyl.Approved, Investigational, Vet Approved
EstriolThe serum concentration of Estriol can be increased when it is combined with Fentanyl.Approved, Vet Approved
EstroneThe serum concentration of Estrone can be increased when it is combined with Fentanyl.Approved
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Fentanyl.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Fentanyl is combined with Etacrynic acid.Approved
EtanautineThe risk or severity of adverse effects can be increased when Etanautine is combined with Fentanyl.Experimental
EthanolFentanyl may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Fentanyl is combined with Ethchlorvynol.Approved, Illicit, Withdrawn
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Fentanyl.Approved
EthopropazineThe risk or severity of adverse effects can be increased when Ethopropazine is combined with Fentanyl.Approved
EthosuximideThe risk or severity of adverse effects can be increased when Fentanyl is combined with Ethosuximide.Approved
EthotoinThe risk or severity of adverse effects can be increased when Fentanyl is combined with Ethotoin.Approved
EthoxzolamideThe risk or severity of adverse effects can be increased when Fentanyl is combined with Ethoxzolamide.Withdrawn
Ethyl carbamateThe risk or severity of adverse effects can be increased when Fentanyl is combined with Ethyl carbamate.Withdrawn
Ethyl chlorideThe risk or severity of adverse effects can be increased when Fentanyl is combined with Ethyl chloride.Experimental
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Fentanyl is combined with Ethyl loflazepate.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Ethylmorphine.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Etidocaine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Etifoxine.Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Fentanyl is combined with Etizolam.Approved
EtomidateThe risk or severity of adverse effects can be increased when Fentanyl is combined with Etomidate.Approved
EtoperidoneFentanyl may increase the serotonergic activities of Etoperidone.Approved
EtoposideThe serum concentration of Etoposide can be increased when it is combined with Fentanyl.Approved
EtorphineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Etorphine.Illicit, Vet Approved
EtybenzatropineThe risk or severity of adverse effects can be increased when Etybenzatropine is combined with Fentanyl.Experimental
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Fentanyl.Approved
EzetimibeThe serum concentration of Ezetimibe can be increased when it is combined with Fentanyl.Approved
EzogabineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Ezogabine.Approved
FelbamateThe risk or severity of adverse effects can be increased when Fentanyl is combined with Felbamate.Approved
FencamfamineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Fencamfamine.Approved, Illicit, Withdrawn
FenquizoneThe risk or severity of adverse effects can be increased when Fentanyl is combined with Fenquizone.Experimental
FesoterodineThe serum concentration of Fesoterodine can be increased when it is combined with Fentanyl.Approved
FexofenadineThe serum concentration of Fexofenadine can be increased when it is combined with Fentanyl.Approved
FidaxomicinThe serum concentration of Fidaxomicin can be increased when it is combined with Fentanyl.Approved
FlibanserinThe risk or severity of adverse effects can be increased when Fentanyl is combined with Flibanserin.Approved
FluanisoneThe risk or severity of adverse effects can be increased when Fentanyl is combined with Fluanisone.Experimental
FluconazoleThe serum concentration of Fentanyl can be increased when it is combined with Fluconazole.Approved
FludiazepamThe risk or severity of adverse effects can be increased when Fentanyl is combined with Fludiazepam.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Flunarizine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Fentanyl is combined with Flunitrazepam.Approved, Illicit
FluoxetineThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Fentanyl.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Fentanyl is combined with Flupentixol.Approved, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Fentanyl.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Fentanyl.Approved, Illicit
FluspirileneThe risk or severity of adverse effects can be increased when Fentanyl is combined with Fluspirilene.Approved
Fluticasone furoateThe serum concentration of Fluticasone furoate can be increased when it is combined with Fentanyl.Approved
Fluticasone propionateThe risk or severity of adverse effects can be increased when Fentanyl is combined with Fluticasone propionate.Approved
FluvastatinThe serum concentration of Fluvastatin can be increased when it is combined with Fentanyl.Approved
FluvoxamineThe serum concentration of Fentanyl can be increased when it is combined with Fluvoxamine.Approved, Investigational
FosamprenavirThe serum concentration of Fentanyl can be increased when it is combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Fentanyl can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe serum concentration of Fentanyl can be decreased when it is combined with Fosphenytoin.Approved
FospropofolThe risk or severity of adverse effects can be increased when Fentanyl is combined with Fospropofol.Approved, Illicit
FrovatriptanThe risk or severity of adverse effects can be increased when Fentanyl is combined with Frovatriptan.Approved, Investigational
FurazolidoneFentanyl may increase the serotonergic activities of Furazolidone.Approved, Vet Approved
FurosemideThe risk or severity of adverse effects can be increased when Fentanyl is combined with Furosemide.Approved, Vet Approved
Fusidic AcidThe serum concentration of Fentanyl can be increased when it is combined with Fusidic Acid.Approved
GabapentinThe risk or severity of adverse effects can be increased when Fentanyl is combined with Gabapentin.Approved, Investigational
Gabapentin EnacarbilThe risk or severity of adverse effects can be increased when Fentanyl is combined with Gabapentin Enacarbil.Approved
GallamineThe risk or severity of adverse effects can be increased when Gallamine is combined with Fentanyl.Experimental
Gallamine TriethiodideThe risk or severity of adverse effects can be increased when Gallamine Triethiodide is combined with Fentanyl.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Fentanyl is combined with Gamma Hydroxybutyric Acid.Approved, Illicit
GefitinibThe serum concentration of Gefitinib can be increased when it is combined with Fentanyl.Approved, Investigational
GemcitabineThe serum concentration of Gemcitabine can be increased when it is combined with Fentanyl.Approved
GepefrineGepefrine may increase the analgesic activities of Fentanyl.Experimental
GepironeThe risk or severity of adverse effects can be increased when Fentanyl is combined with Gepirone.Investigational
GlecaprevirThe serum concentration of Glecaprevir can be increased when it is combined with Fentanyl.Approved
GlutethimideThe risk or severity of adverse effects can be increased when Fentanyl is combined with Glutethimide.Approved, Illicit
GlycopyrroniumThe risk or severity of adverse effects can be increased when Glycopyrronium is combined with Fentanyl.Approved, Investigational, Vet Approved
GranisetronGranisetron may increase the serotonergic activities of Fentanyl.Approved, Investigational
GrazoprevirThe serum concentration of Grazoprevir can be increased when it is combined with Fentanyl.Approved
GrepafloxacinThe serum concentration of Grepafloxacin can be increased when it is combined with Fentanyl.Withdrawn
GuanfacineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Guanfacine.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Fentanyl is combined with Halazepam.Approved, Illicit, Withdrawn
HaloperidolThe serum concentration of Haloperidol can be increased when it is combined with Fentanyl.Approved
HalothaneThe risk or severity of adverse effects can be increased when Fentanyl is combined with Halothane.Approved, Vet Approved
HarmalineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Harmaline.Experimental
HeroinThe risk or severity of adverse effects can be increased when Fentanyl is combined with Heroin.Approved, Illicit
HexamethoniumThe risk or severity of adverse effects can be increased when Hexamethonium is combined with Fentanyl.Experimental
HexobarbitalThe risk or severity of adverse effects can be increased when Fentanyl is combined with Hexobarbital.Approved
HomatropineThe risk or severity of adverse effects can be increased when Homatropine is combined with Fentanyl.Approved
HydracarbazineFentanyl may increase the serotonergic activities of Hydracarbazine.Experimental
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Fentanyl is combined with Hydrochlorothiazide.Approved, Vet Approved
HydrocodoneFentanyl may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydrocortisoneThe serum concentration of Hydrocortisone can be increased when it is combined with Fentanyl.Approved, Vet Approved
HydroflumethiazideThe risk or severity of adverse effects can be increased when Fentanyl is combined with Hydroflumethiazide.Approved
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Fentanyl.Approved, Illicit
HydroxyamphetamineHydroxyamphetamine may increase the analgesic activities of Fentanyl.Approved
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Fentanyl.Approved
HyoscyamineThe risk or severity of adverse effects can be increased when Hyoscyamine is combined with Fentanyl.Approved
IbopamineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Ibopamine.Experimental
IbuprofenThe serum concentration of Ibuprofen can be increased when it is combined with Fentanyl.Approved
IloperidoneThe risk or severity of adverse effects can be increased when Fentanyl is combined with Iloperidone.Approved
ImatinibThe serum concentration of Fentanyl can be increased when it is combined with Imatinib.Approved
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Fentanyl.Approved
IndacaterolThe serum concentration of Indacaterol can be increased when it is combined with Fentanyl.Approved
IndalpineFentanyl may increase the serotonergic activities of Indalpine.Investigational, Withdrawn
IndapamideThe risk or severity of adverse effects can be increased when Fentanyl is combined with Indapamide.Approved
IndenololFentanyl may increase the bradycardic activities of Indenolol.Withdrawn
IndinavirThe serum concentration of Fentanyl can be increased when it is combined with Indinavir.Approved
IndiplonThe risk or severity of adverse effects can be increased when Fentanyl is combined with Indiplon.Investigational
IndomethacinThe serum concentration of Indomethacin can be increased when it is combined with Fentanyl.Approved, Investigational
Inotuzumab ozogamicinThe serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Fentanyl.Approved
Iofetamine I-123Iofetamine I-123 may increase the analgesic activities of Fentanyl.Approved
Ioflupane I-123Fentanyl may decrease effectiveness of Ioflupane I-123 as a diagnostic agent.Approved
Ipratropium bromideThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Fentanyl.Approved
IproclozideFentanyl may increase the serotonergic activities of Iproclozide.Withdrawn
IproniazidFentanyl may increase the serotonergic activities of Iproniazid.Withdrawn
IrinotecanThe serum concentration of Irinotecan can be increased when it is combined with Fentanyl.Approved, Investigational
IsavuconazoniumThe serum concentration of Fentanyl can be increased when it is combined with Isavuconazonium.Approved, Investigational
IsocarboxazidThe risk or severity of adverse effects can be increased when Fentanyl is combined with Isocarboxazid.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Fentanyl.Approved, Vet Approved
IsosorbideThe risk or severity of adverse effects can be increased when Fentanyl is combined with Isosorbide.Approved
IsradipineThe serum concentration of Fentanyl can be increased when it is combined with Isradipine.Approved
ItraconazoleThe serum concentration of Fentanyl can be increased when it is combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Fentanyl can be increased when it is combined with Ivacaftor.Approved
IvermectinThe serum concentration of Ivermectin can be increased when it is combined with Fentanyl.Approved, Vet Approved
KetamineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Ketamine.Approved, Vet Approved
KetazolamThe serum concentration of Ketazolam can be increased when it is combined with Fentanyl.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Fentanyl is combined with Ketobemidone.Approved
KetoconazoleThe serum concentration of Fentanyl can be increased when it is combined with Ketoconazole.Approved, Investigational
LabetalolFentanyl may increase the bradycardic activities of Labetalol.Approved
LamivudineThe serum concentration of Lamivudine can be increased when it is combined with Fentanyl.Approved, Investigational
LamotrigineThe serum concentration of Lamotrigine can be increased when it is combined with Fentanyl.Approved, Investigational
LandiololFentanyl may increase the bradycardic activities of Landiolol.Investigational
LansoprazoleThe serum concentration of Lansoprazole can be increased when it is combined with Fentanyl.Approved, Investigational
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Fentanyl.Approved
LenalidomideThe serum concentration of Lenalidomide can be increased when it is combined with Fentanyl.Approved
LenvatinibThe serum concentration of Lenvatinib can be increased when it is combined with Fentanyl.Approved
LevetiracetamThe serum concentration of Levetiracetam can be increased when it is combined with Fentanyl.Approved, Investigational
LevobunololFentanyl may increase the bradycardic activities of Levobunolol.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Levobupivacaine.Approved
LevocabastineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Levocabastine.Approved
LevocetirizineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Levocetirizine.Approved
LevodopaThe risk or severity of adverse effects can be increased when Fentanyl is combined with Levodopa.Approved
LevofloxacinThe serum concentration of Levofloxacin can be increased when it is combined with Fentanyl.Approved, Investigational
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Fentanyl is combined with Levomethadyl Acetate.Approved
LevomilnacipranThe risk or severity of adverse effects can be increased when Fentanyl is combined with Levomilnacipran.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Fentanyl is combined with Levorphanol.Approved
LidocaineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Lidocaine.Approved, Vet Approved
LinagliptinThe serum concentration of Linagliptin can be increased when it is combined with Fentanyl.Approved
LinezolidThe risk or severity of adverse effects can be increased when Linezolid is combined with Fentanyl.Approved, Investigational
LisdexamfetamineLisdexamfetamine may increase the analgesic activities of Fentanyl.Approved, Investigational
LisurideThe risk or severity of adverse effects can be increased when Lisuride is combined with Fentanyl.Approved
LithiumThe risk or severity of adverse effects can be increased when Fentanyl is combined with Lithium.Approved
LofentanilThe risk or severity of adverse effects can be increased when Fentanyl is combined with Lofentanil.Illicit
LoperamideThe serum concentration of Loperamide can be increased when it is combined with Fentanyl.Approved
LopinavirThe serum concentration of Fentanyl can be increased when it is combined with Lopinavir.Approved
LoprazolamThe risk or severity of adverse effects can be increased when Fentanyl is combined with Loprazolam.Experimental
LoratadineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Loratadine.Approved
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Fentanyl.Approved
LorcaserinThe risk or severity of adverse effects can be increased when Fentanyl is combined with Lorcaserin.Approved
LormetazepamThe risk or severity of adverse effects can be increased when Fentanyl is combined with Lormetazepam.Approved
LosartanThe serum concentration of Losartan can be increased when it is combined with Fentanyl.Approved
LovastatinThe serum concentration of Fentanyl can be increased when it is combined with Lovastatin.Approved, Investigational
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Fentanyl.Approved
LuliconazoleThe serum concentration of Fentanyl can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Fentanyl can be decreased when it is combined with Lumacaftor.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Fentanyl is combined with Lurasidone.Approved
Lysergic Acid DiethylamideThe risk or severity of adverse effects can be increased when Lysergic Acid Diethylamide is combined with Fentanyl.Illicit, Withdrawn
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Fentanyl.Approved, Vet Approved
MannitolThe risk or severity of adverse effects can be increased when Fentanyl is combined with Mannitol.Approved, Investigational
MaprotilineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Maprotiline.Approved
MazaticolThe risk or severity of adverse effects can be increased when Mazaticol is combined with Fentanyl.Experimental
MebanazineFentanyl may increase the serotonergic activities of Mebanazine.Withdrawn
MebicarThe risk or severity of adverse effects can be increased when Fentanyl is combined with Mebicar.Experimental
MebutizideThe risk or severity of adverse effects can be increased when Fentanyl is combined with Mebutizide.Experimental
MecamylamineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Fentanyl.Approved
MeclizineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Meclizine.Approved
MedazepamThe risk or severity of adverse effects can be increased when Fentanyl is combined with Medazepam.Experimental
MedetomidineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Medetomidine.Vet Approved
MefrusideThe risk or severity of adverse effects can be increased when Fentanyl is combined with Mefruside.Experimental
MelatoninThe risk or severity of adverse effects can be increased when Fentanyl is combined with Melatonin.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Fentanyl is combined with Melperone.Approved
MephedroneMephedrone may increase the analgesic activities of Fentanyl.Investigational
MephentermineThe serum concentration of Fentanyl can be decreased when it is combined with Mephentermine.Approved
MepindololFentanyl may increase the bradycardic activities of Mepindolol.Experimental
MepivacaineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Mepivacaine.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Fentanyl.Approved, Illicit
MeptazinolThe risk or severity of adverse effects can be increased when Fentanyl is combined with Meptazinol.Experimental
MersalylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Mersalyl.Approved
MesoridazineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Mesoridazine.Approved
MetaraminolThe serum concentration of Fentanyl can be decreased when it is combined with Metaraminol.Approved, Investigational
MetaxaloneThe risk or severity of adverse effects can be increased when Fentanyl is combined with Metaxalone.Approved
MetergolineThe risk or severity of adverse effects can be increased when Metergoline is combined with Fentanyl.Experimental
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Fentanyl.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Fentanyl is combined with Methadyl Acetate.Approved, Illicit
MethamphetamineMethamphetamine may increase the analgesic activities of Fentanyl.Approved, Illicit
MethanthelineThe risk or severity of adverse effects can be increased when Methantheline is combined with Fentanyl.Approved
MethapyrileneThe risk or severity of adverse effects can be increased when Fentanyl is combined with Methapyrilene.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Fentanyl is combined with Methaqualone.Illicit, Withdrawn
MethazolamideThe risk or severity of adverse effects can be increased when Fentanyl is combined with Methazolamide.Approved
MethocarbamolThe risk or severity of adverse effects can be increased when Fentanyl is combined with Methocarbamol.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Fentanyl.Approved
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Fentanyl.Approved
MethotrimeprazineFentanyl may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxamineThe serum concentration of Fentanyl can be decreased when it is combined with Methoxamine.Approved
MethoxyfluraneThe risk or severity of adverse effects can be increased when Fentanyl is combined with Methoxyflurane.Approved, Vet Approved
MethoxyphenamineMethoxyphenamine may increase the analgesic activities of Fentanyl.Experimental
MethsuximideThe risk or severity of adverse effects can be increased when Fentanyl is combined with Methsuximide.Approved
MethyclothiazideThe risk or severity of adverse effects can be increased when Fentanyl is combined with Methyclothiazide.Approved
MethylecgonineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Methylecgonine.Experimental
Methylene blueMethylene blue may increase the hypotensive activities of Fentanyl.Investigational
MethylergometrineThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Fentanyl.Approved
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Fentanyl is combined with Methylphenobarbital.Approved
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Fentanyl.Approved, Vet Approved
MethysergideThe risk or severity of adverse effects can be increased when Methysergide is combined with Fentanyl.Approved
MeticraneThe risk or severity of adverse effects can be increased when Fentanyl is combined with Meticrane.Experimental
MetipranololFentanyl may increase the bradycardic activities of Metipranolol.Approved
MetixeneThe risk or severity of adverse effects can be increased when Metixene is combined with Fentanyl.Approved
MetoclopramideThe risk or severity of adverse effects can be increased when Fentanyl is combined with Metoclopramide.Approved, Investigational
MetolazoneThe risk or severity of adverse effects can be increased when Fentanyl is combined with Metolazone.Approved
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Fentanyl.Approved, Investigational
MetyrosineFentanyl may increase the sedative activities of Metyrosine.Approved
MevastatinThe serum concentration of Mevastatin can be increased when it is combined with Fentanyl.Experimental
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Fentanyl.Approved, Illicit
MidodrineThe serum concentration of Fentanyl can be decreased when it is combined with Midodrine.Approved
Midomafetamine3,4-Methylenedioxymethamphetamine may increase the analgesic activities of Fentanyl.Experimental, Illicit
MifepristoneThe serum concentration of Fentanyl can be increased when it is combined with Mifepristone.Approved, Investigational
MilnacipranThe risk or severity of adverse effects can be increased when Fentanyl is combined with Milnacipran.Approved
MinaprineFentanyl may increase the serotonergic activities of Minaprine.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Fentanyl.Approved, Investigational
MirabegronThe serum concentration of Mirabegron can be increased when it is combined with Fentanyl.Approved
MirtazapineFentanyl may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MitotaneThe serum concentration of Fentanyl can be decreased when it is combined with Mitotane.Approved
MitoxantroneThe serum concentration of Mitoxantrone can be increased when it is combined with Fentanyl.Approved, Investigational
MMDAMMDA may increase the analgesic activities of Fentanyl.Experimental, Illicit
MoclobemideThe risk or severity of adverse effects can be increased when Fentanyl is combined with Moclobemide.Approved
MolindoneThe risk or severity of adverse effects can be increased when Fentanyl is combined with Molindone.Approved
MoperoneThe risk or severity of adverse effects can be increased when Fentanyl is combined with Moperone.Experimental
MoricizineMoricizine may increase the hypotensive activities of Fentanyl.Approved, Withdrawn
MorphineThe serum concentration of Morphine can be increased when it is combined with Fentanyl.Approved, Investigational
MosapramineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Mosapramine.Experimental
MuzolimineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Muzolimine.Experimental
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Fentanyl.Approved, Investigational
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Fentanyl.Approved, Investigational
NadololThe serum concentration of Nadolol can be increased when it is combined with Fentanyl.Approved
NalbuphineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Nalbuphine.Approved
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Fentanyl.Approved
NaloxoneThe serum concentration of Naloxone can be increased when it is combined with Fentanyl.Approved, Vet Approved
NaltrexoneThe therapeutic efficacy of Fentanyl can be decreased when used in combination with Naltrexone.Approved, Investigational, Vet Approved
NaratriptanThe risk or severity of adverse effects can be increased when Fentanyl is combined with Naratriptan.Approved, Investigational
NefazodoneThe serum concentration of Fentanyl can be increased when it is combined with Nefazodone.Approved, Withdrawn
NelfinavirThe serum concentration of Fentanyl can be increased when it is combined with Nelfinavir.Approved
NetupitantThe serum concentration of Fentanyl can be increased when it is combined with Netupitant.Approved
NevirapineThe serum concentration of Fentanyl can be increased when it is combined with Nevirapine.Approved
NialamideFentanyl may increase the serotonergic activities of Nialamide.Withdrawn
NicardipineThe serum concentration of Nicardipine can be increased when it is combined with Fentanyl.Approved
NicergolineThe risk or severity of adverse effects can be increased when Nicergoline is combined with Fentanyl.Approved
NifedipineThe serum concentration of Nifedipine can be increased when it is combined with Fentanyl.Approved
NilotinibThe serum concentration of Fentanyl can be increased when it is combined with Nilotinib.Approved, Investigational
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Fentanyl.Approved
NitrazepamThe risk or severity of adverse effects can be increased when Fentanyl is combined with Nitrazepam.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Fentanyl is combined with Nitrous oxide.Approved, Vet Approved
NizatidineThe serum concentration of Nizatidine can be increased when it is combined with Fentanyl.Approved
NorfluraneThe risk or severity of adverse effects can be increased when Fentanyl is combined with Norflurane.Investigational
NormethadoneThe risk or severity of adverse effects can be increased when Fentanyl is combined with Normethadone.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Fentanyl.Approved
OctamoxinFentanyl may increase the serotonergic activities of Octamoxin.Withdrawn
OdanacatibThe serum concentration of Odanacatib can be increased when it is combined with Fentanyl.Investigational
OlanzapineThe serum concentration of Olanzapine can be increased when it is combined with Fentanyl.Approved, Investigational
OlaparibThe serum concentration of Fentanyl can be increased when it is combined with Olaparib.Approved
OlopatadineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Olopatadine.Approved
OmbitasvirThe serum concentration of Fentanyl can be increased when it is combined with Ombitasvir.Approved
OndansetronOndansetron may increase the serotonergic activities of Fentanyl.Approved
OpiumThe risk or severity of adverse effects can be increased when Fentanyl is combined with Opium.Approved, Illicit
OrphenadrineFentanyl may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Fentanyl is combined with Osanetant.Investigational
OsimertinibThe serum concentration of Fentanyl can be increased when it is combined with Osimertinib.Approved
OtiloniumThe risk or severity of adverse effects can be increased when Otilonium is combined with Fentanyl.Experimental
OxazepamThe risk or severity of adverse effects can be increased when Fentanyl is combined with Oxazepam.Approved
OxethazaineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Oxethazaine.Investigational
OxitropiumThe risk or severity of adverse effects can be increased when Oxitropium is combined with Fentanyl.Investigational
OxprenololThe risk or severity of adverse effects can be increased when Fentanyl is combined with Oxprenolol.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Oxybuprocaine.Approved
OxybutyninThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Fentanyl.Approved, Investigational
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Fentanyl.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Fentanyl is combined with Oxymorphone.Approved, Investigational, Vet Approved
OxypertineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Oxypertine.Experimental
OxyphenoniumThe risk or severity of adverse effects can be increased when Oxyphenonium is combined with Fentanyl.Approved
PaclitaxelThe serum concentration of Paclitaxel can be increased when it is combined with Fentanyl.Approved, Vet Approved
PalbociclibThe serum concentration of Fentanyl can be increased when it is combined with Palbociclib.Approved
PaliperidoneThe risk or severity of adverse effects can be increased when Fentanyl is combined with Paliperidone.Approved
PalonosetronPalonosetron may increase the serotonergic activities of Fentanyl.Approved, Investigational
PancuroniumThe risk or severity of adverse effects can be increased when Pancuronium is combined with Fentanyl.Approved
PanobinostatThe serum concentration of Panobinostat can be increased when it is combined with Fentanyl.Approved, Investigational
ParaldehydeFentanyl may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved
PargylineFentanyl may increase the serotonergic activities of Pargyline.Approved
ParitaprevirThe serum concentration of Fentanyl can be increased when it is combined with Paritaprevir.Approved
ParoxetineThe risk or severity of adverse effects can be increased when Paroxetine is combined with Fentanyl.Approved, Investigational
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Fentanyl.Approved
PegvisomantThe therapeutic efficacy of Pegvisomant can be decreased when used in combination with Fentanyl.Approved
PenbutololFentanyl may increase the bradycardic activities of Penbutolol.Approved, Investigational
PenfluridolThe risk or severity of adverse effects can be increased when Fentanyl is combined with Penfluridol.Experimental
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Fentanyl.Approved, Vet Approved
PentobarbitalThe serum concentration of Fentanyl can be decreased when it is combined with Pentobarbital.Approved, Vet Approved
PentoliniumThe risk or severity of adverse effects can be increased when Pentolinium is combined with Fentanyl.Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Fentanyl.Approved
PerazineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Perazine.Investigational
PergolideThe risk or severity of adverse effects can be increased when Pergolide is combined with Fentanyl.Approved, Vet Approved, Withdrawn
PerospironeThe risk or severity of adverse effects can be increased when Fentanyl is combined with Perospirone.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Perphenazine.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Fentanyl.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Phenazocine.Experimental
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Fentanyl.Approved
PhenglutarimideThe risk or severity of adverse effects can be increased when Phenglutarimide is combined with Fentanyl.Experimental
PhenibutThe risk or severity of adverse effects can be increased when Fentanyl is combined with Phenibut.Experimental
PheniprazineFentanyl may increase the serotonergic activities of Pheniprazine.Withdrawn
PhenobarbitalThe serum concentration of Fentanyl can be decreased when it is combined with Phenobarbital.Approved
PhenoperidineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Phenoperidine.Experimental
PhenoxyethanolThe risk or severity of adverse effects can be increased when Fentanyl is combined with Phenoxyethanol.Approved
PhenoxypropazineFentanyl may increase the serotonergic activities of Phenoxypropazine.Withdrawn
PhenterminePhentermine may increase the analgesic activities of Fentanyl.Approved, Illicit
PhenylephrineThe serum concentration of Fentanyl can be decreased when it is combined with Phenylephrine.Approved
PhenytoinThe serum concentration of Fentanyl can be decreased when it is combined with Phenytoin.Approved, Vet Approved
PibrentasvirThe serum concentration of Pibrentasvir can be increased when it is combined with Fentanyl.Approved
PimozideThe risk or severity of adverse effects can be increased when Fentanyl is combined with Pimozide.Approved
PindololFentanyl may increase the bradycardic activities of Pindolol.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Fentanyl is combined with Pipamperone.Approved
PipecuroniumThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Fentanyl.Approved
PipotiazineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Pipotiazine.Approved
PirenzepineThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Fentanyl.Approved
PiretanideThe risk or severity of adverse effects can be increased when Fentanyl is combined with Piretanide.Experimental
PiritramideThe risk or severity of adverse effects can be increased when Fentanyl is combined with Piritramide.Investigational
PirlindoleFentanyl may increase the serotonergic activities of Pirlindole.Approved
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Fentanyl.Approved
PivhydrazineFentanyl may increase the serotonergic activities of Pivhydrazine.Withdrawn
PizotifenThe risk or severity of adverse effects can be increased when Fentanyl is combined with Pizotifen.Approved
PolythiazideThe risk or severity of adverse effects can be increased when Fentanyl is combined with Polythiazide.Approved
PomalidomideThe serum concentration of Pomalidomide can be increased when it is combined with Fentanyl.Approved
PonatinibThe serum concentration of Ponatinib can be increased when it is combined with Fentanyl.Approved
PosaconazoleThe serum concentration of Fentanyl can be increased when it is combined with Posaconazole.Approved, Investigational, Vet Approved
PotassiumThe risk or severity of adverse effects can be increased when Fentanyl is combined with Potassium.Approved
Potassium CitrateThe risk or severity of adverse effects can be increased when Fentanyl is combined with Potassium Citrate.Approved, Vet Approved
PractololFentanyl may increase the bradycardic activities of Practolol.Approved
PramipexoleFentanyl may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Pramocaine.Approved
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Fentanyl.Approved
PrazepamThe risk or severity of adverse effects can be increased when Fentanyl is combined with Prazepam.Approved, Illicit
PrazosinThe serum concentration of Prazosin can be increased when it is combined with Fentanyl.Approved
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Fentanyl.Approved, Vet Approved
PrednisoneThe serum concentration of Prednisone can be increased when it is combined with Fentanyl.Approved, Vet Approved
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Fentanyl.Approved, Illicit, Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Prilocaine.Approved
PrimidoneThe serum concentration of Fentanyl can be decreased when it is combined with Primidone.Approved, Vet Approved
ProcaineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Procaine.Approved, Investigational, Vet Approved
ProcarbazineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Procarbazine.Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Fentanyl.Approved, Vet Approved
ProcyclidineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Fentanyl.Approved
ProgesteroneThe serum concentration of Progesterone can be increased when it is combined with Fentanyl.Approved, Vet Approved
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Fentanyl.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Promethazine.Approved
PropanididThe risk or severity of adverse effects can be increased when Fentanyl is combined with Propanidid.Experimental
PropanthelineThe risk or severity of adverse effects can be increased when Propantheline is combined with Fentanyl.Approved
ProparacaineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Proparacaine.Approved, Vet Approved
PropericiazineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Propericiazine.Approved
PropiopromazinePropiopromazine may increase the hypotensive activities of Fentanyl.Vet Approved
PropiverineThe risk or severity of adverse effects can be increased when Propiverine is combined with Fentanyl.Investigational
PropofolThe risk or severity of adverse effects can be increased when Fentanyl is combined with Propofol.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Propoxycaine.Approved
PropranololThe serum concentration of Propranolol can be increased when it is combined with Fentanyl.Approved, Investigational
ProthipendylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Prothipendyl.Investigational
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Fentanyl.Approved
ProxibarbalThe risk or severity of adverse effects can be increased when Fentanyl is combined with Proxibarbal.Experimental
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Fentanyl.Approved
PSD502The risk or severity of adverse effects can be increased when Fentanyl is combined with PSD502.Investigational
PseudoephedrinePseudoephedrine may increase the analgesic activities of Fentanyl.Approved
QuazepamThe risk or severity of adverse effects can be increased when Fentanyl is combined with Quazepam.Approved, Illicit
QuetiapineThe serum concentration of Quetiapine can be increased when it is combined with Fentanyl.Approved
QuinethazoneThe risk or severity of adverse effects can be increased when Fentanyl is combined with Quinethazone.Approved
QuinidineThe serum concentration of Quinidine can be increased when it is combined with Fentanyl.Approved
QuinineThe serum concentration of Quinine can be increased when it is combined with Fentanyl.Approved
QuinisocaineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Quinisocaine.Experimental
RacloprideThe risk or severity of adverse effects can be increased when Fentanyl is combined with Raclopride.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Fentanyl is combined with Ramelteon.Approved, Investigational
RamosetronFentanyl may increase the constipating activities of Ramosetron.Approved
RanitidineThe serum concentration of Ranitidine can be increased when it is combined with Fentanyl.Approved
RanolazineThe serum concentration of Fentanyl can be increased when it is combined with Ranolazine.Approved, Investigational
RasagilineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Rasagiline.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Fentanyl is combined with Remifentanil.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Fentanyl is combined with Remoxipride.Approved, Withdrawn
ReserpineThe serum concentration of Reserpine can be increased when it is combined with Fentanyl.Approved
RifabutinThe serum concentration of Fentanyl can be decreased when it is combined with Rifabutin.Approved
RifampicinThe serum concentration of Fentanyl can be decreased when it is combined with Rifampicin.Approved
RifapentineThe serum concentration of Fentanyl can be decreased when it is combined with Rifapentine.Approved
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Fentanyl.Approved, Investigational
RisperidoneThe serum concentration of Risperidone can be increased when it is combined with Fentanyl.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Fentanyl is combined with Ritanserin.Investigational
RitobegronRitobegron may increase the analgesic activities of Fentanyl.Investigational
RitonavirThe serum concentration of Fentanyl can be increased when it is combined with Ritonavir.Approved, Investigational
RivaroxabanThe serum concentration of Rivaroxaban can be increased when it is combined with Fentanyl.Approved
RizatriptanThe risk or severity of adverse effects can be increased when Fentanyl is combined with Rizatriptan.Approved
RolofyllineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Rolofylline.Investigational
RomidepsinThe serum concentration of Romidepsin can be increased when it is combined with Fentanyl.Approved, Investigational
RomifidineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Romifidine.Vet Approved
RopiniroleFentanyl may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Ropivacaine.Approved
RosuvastatinThe serum concentration of Rosuvastatin can be increased when it is combined with Fentanyl.Approved
RotigotineFentanyl may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Fentanyl.Approved
SafrazineFentanyl may increase the serotonergic activities of Safrazine.Withdrawn
Salicylic acidThe serum concentration of Salicylic acid can be increased when it is combined with Fentanyl.Approved, Vet Approved
SaquinavirThe serum concentration of Fentanyl can be increased when it is combined with Saquinavir.Approved, Investigational
ScopolamineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Scopolamine.Approved
Scopolamine butylbromideThe risk or severity of adverse effects can be increased when Scopolamine butylbromide is combined with Fentanyl.Approved, Vet Approved
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Fentanyl.Approved, Vet Approved
SelegilineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Selegiline.Approved, Investigational, Vet Approved
SelexipagThe serum concentration of Selexipag can be increased when it is combined with Fentanyl.Approved
SepranoloneThe risk or severity of adverse effects can be increased when Fentanyl is combined with Sepranolone.Investigational
SertindoleThe risk or severity of adverse effects can be increased when Fentanyl is combined with Sertindole.Approved, Withdrawn
SertralineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Fentanyl is combined with Sevoflurane.Approved, Vet Approved
SildenafilThe serum concentration of Fentanyl can be increased when it is combined with Sildenafil.Approved, Investigational
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Fentanyl.Approved
SiltuximabThe serum concentration of Fentanyl can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Fentanyl can be increased when it is combined with Simeprevir.Approved
SimvastatinThe serum concentration of Simvastatin can be increased when it is combined with Fentanyl.Approved
SitagliptinThe serum concentration of Sitagliptin can be increased when it is combined with Fentanyl.Approved, Investigational
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Fentanyl.Approved
SofosbuvirThe serum concentration of Sofosbuvir can be increased when it is combined with Fentanyl.Approved
SolifenacinThe risk or severity of adverse effects can be increased when Solifenacin is combined with Fentanyl.Approved
SorafenibThe serum concentration of Sorafenib can be increased when it is combined with Fentanyl.Approved, Investigational
SotalolFentanyl may increase the bradycardic activities of Sotalol.Approved
SparfloxacinThe serum concentration of Sparfloxacin can be increased when it is combined with Fentanyl.Approved
SphingosineThe serum concentration of Sphingosine can be increased when it is combined with Fentanyl.Experimental
SpiradolineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Spiradoline.Investigational
SpironolactoneThe risk or severity of adverse effects can be increased when Fentanyl is combined with Spironolactone.Approved
St. John's WortThe serum concentration of Fentanyl can be decreased when it is combined with St. John's Wort.Nutraceutical
StiripentolThe serum concentration of Fentanyl can be increased when it is combined with Stiripentol.Approved
SuccinylcholineSuccinylcholine may increase the bradycardic activities of Fentanyl.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Fentanyl.Approved, Investigational
SulfisoxazoleThe serum concentration of Fentanyl can be increased when it is combined with Sulfisoxazole.Approved, Vet Approved
SulpirideThe risk or severity of adverse effects can be increased when Fentanyl is combined with Sulpiride.Approved
SultoprideThe risk or severity of adverse effects can be increased when Fentanyl is combined with Sultopride.Experimental
SumatriptanThe risk or severity of adverse effects can be increased when Sumatriptan is combined with Fentanyl.Approved, Investigational
SuvorexantFentanyl may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
TacrolimusThe serum concentration of Tacrolimus can be increased when it is combined with Fentanyl.Approved, Investigational
TalinololFentanyl may increase the bradycardic activities of Talinolol.Investigational
TamoxifenThe serum concentration of Tamoxifen can be increased when it is combined with Fentanyl.Approved
TandospironeThe risk or severity of adverse effects can be increased when Fentanyl is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Fentanyl.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Fentanyl is combined with Tasimelteon.Approved
Taurocholic AcidThe serum concentration of Taurocholic Acid can be increased when it is combined with Fentanyl.Experimental
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Fentanyl.Approved
Tedizolid PhosphateTedizolid Phosphate may increase the serotonergic activities of Fentanyl.Approved
TelaprevirThe serum concentration of Fentanyl can be increased when it is combined with Telaprevir.Withdrawn
TelithromycinThe serum concentration of Fentanyl can be increased when it is combined with Telithromycin.Approved
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Fentanyl.Approved
TemsirolimusThe serum concentration of Temsirolimus can be increased when it is combined with Fentanyl.Approved
TergurideThe risk or severity of adverse effects can be increased when Terguride is combined with Fentanyl.Experimental
TertatololFentanyl may increase the bradycardic activities of Tertatolol.Experimental
TetrabenazineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Tetrabenazine.Approved
TetracaineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Tetracaine.Approved, Vet Approved
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Tetrahydropalmatine.Investigational
TetrodotoxinThe risk or severity of adverse effects can be increased when Fentanyl is combined with Tetrodotoxin.Investigational
ThalidomideFentanyl may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
TheobromineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Theobromine.Approved
ThiamylalThe risk or severity of adverse effects can be increased when Fentanyl is combined with Thiamylal.Approved, Vet Approved
ThiazinamThiazinam may increase the hypotensive activities of Fentanyl.Experimental
ThiethylperazineThiethylperazine may increase the hypotensive activities of Fentanyl.Withdrawn
ThiopentalThe risk or severity of adverse effects can be increased when Fentanyl is combined with Thiopental.Approved, Vet Approved
ThiopropazateThe risk or severity of adverse effects can be increased when Fentanyl is combined with Thiopropazate.Experimental
ThioproperazineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Thioproperazine.Approved
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Fentanyl.Withdrawn
ThiothixeneThe risk or severity of adverse effects can be increased when Fentanyl is combined with Thiothixene.Approved
TiagabineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Tiagabine.Approved
TiaprideThe risk or severity of adverse effects can be increased when Fentanyl is combined with Tiapride.Approved, Investigational
TicagrelorThe serum concentration of Ticagrelor can be increased when it is combined with Fentanyl.Approved
TiclopidineThe serum concentration of Fentanyl can be increased when it is combined with Ticlopidine.Approved
TicrynafenThe risk or severity of adverse effects can be increased when Fentanyl is combined with Ticrynafen.Withdrawn
TiletamineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Tiletamine.Vet Approved
TilidineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Tilidine.Experimental
TimololThe serum concentration of Timolol can be increased when it is combined with Fentanyl.Approved
TiotropiumThe risk or severity of adverse effects can be increased when Tiotropium is combined with Fentanyl.Approved
TizanidineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Tizanidine.Approved
TocilizumabThe serum concentration of Fentanyl can be decreased when it is combined with Tocilizumab.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Fentanyl is combined with Tolcapone.Approved, Withdrawn
ToloxatoneFentanyl may increase the serotonergic activities of Toloxatone.Approved
TolterodineThe risk or severity of adverse effects can be increased when Tolterodine is combined with Fentanyl.Approved, Investigational
TolvaptanThe risk or severity of adverse effects can be increased when Fentanyl is combined with Tolvaptan.Approved
TopiramateThe risk or severity of adverse effects can be increased when Fentanyl is combined with Topiramate.Approved
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Fentanyl.Approved, Investigational
TorasemideThe risk or severity of adverse effects can be increased when Fentanyl is combined with Torasemide.Approved
ToremifeneThe serum concentration of Toremifene can be increased when it is combined with Fentanyl.Approved, Investigational
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Fentanyl.Approved, Investigational
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Trans-2-Phenylcyclopropylamine.Experimental
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Fentanyl.Approved
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be increased when it is combined with Fentanyl.Approved
TrazodoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Fentanyl.Approved, Investigational
TriamtereneThe risk or severity of adverse effects can be increased when Fentanyl is combined with Triamterene.Approved
TriazolamThe risk or severity of adverse effects can be increased when Fentanyl is combined with Triazolam.Approved
Tricaine methanesulfonateThe risk or severity of adverse effects can be increased when Fentanyl is combined with Tricaine methanesulfonate.Vet Approved
TrichlormethiazideThe risk or severity of adverse effects can be increased when Fentanyl is combined with Trichlormethiazide.Approved, Vet Approved
TrichloroethyleneThe risk or severity of adverse effects can be increased when Fentanyl is combined with Trichloroethylene.Experimental
TrifluoperazineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Trifluoperazine.Approved
TrifluperidolThe risk or severity of adverse effects can be increased when Fentanyl is combined with Trifluperidol.Experimental
TriflupromazineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Triflupromazine.Approved, Vet Approved
TrihexyphenidylThe risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Fentanyl.Approved
TrimethaphanThe risk or severity of adverse effects can be increased when Trimethaphan is combined with Fentanyl.Approved
TrimipramineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Fentanyl.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Triprolidine.Approved
TropatepineThe risk or severity of adverse effects can be increased when Tropatepine is combined with Fentanyl.Experimental
TropicamideThe risk or severity of adverse effects can be increased when Tropicamide is combined with Fentanyl.Approved
TropisetronTropisetron may increase the serotonergic activities of Fentanyl.Approved, Investigational
TrospiumThe risk or severity of adverse effects can be increased when Trospium is combined with Fentanyl.Approved
TubocurarineThe risk or severity of adverse effects can be increased when Tubocurarine is combined with Fentanyl.Approved
UbidecarenoneThe serum concentration of Ubidecarenone can be increased when it is combined with Fentanyl.Experimental
UlaritideThe risk or severity of adverse effects can be increased when Fentanyl is combined with Ularitide.Investigational
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Fentanyl.Approved
UmeclidiniumThe serum concentration of Umeclidinium can be increased when it is combined with Fentanyl.Approved
Valproic AcidThe risk or severity of adverse effects can be increased when Fentanyl is combined with Valproic Acid.Approved, Investigational
VecuroniumThe serum concentration of Vecuronium can be increased when it is combined with Fentanyl.Approved
VelpatasvirThe serum concentration of Velpatasvir can be increased when it is combined with Fentanyl.Approved
VenetoclaxThe serum concentration of Venetoclax can be increased when it is combined with Fentanyl.Approved
VenlafaxineThe serum concentration of Fentanyl can be increased when it is combined with Venlafaxine.Approved
VeraliprideThe risk or severity of adverse effects can be increased when Fentanyl is combined with Veralipride.Experimental
VerapamilThe serum concentration of Fentanyl can be increased when it is combined with Verapamil.Approved
VigabatrinThe risk or severity of adverse effects can be increased when Fentanyl is combined with Vigabatrin.Approved
VilazodoneThe risk or severity of adverse effects can be increased when Fentanyl is combined with Vilazodone.Approved
VinblastineThe serum concentration of Vinblastine can be increased when it is combined with Fentanyl.Approved
VincristineThe serum concentration of Vincristine can be increased when it is combined with Fentanyl.Approved, Investigational
Vinyl etherThe risk or severity of adverse effects can be increased when Fentanyl is combined with Vinyl ether.Experimental
VismodegibThe serum concentration of Vismodegib can be increased when it is combined with Fentanyl.Approved
VoriconazoleThe serum concentration of Fentanyl can be increased when it is combined with Voriconazole.Approved, Investigational
VortioxetineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Vortioxetine.Approved
VoxilaprevirThe serum concentration of Voxilaprevir can be increased when it is combined with Fentanyl.Approved
XenonThe risk or severity of adverse effects can be increased when Fentanyl is combined with Xenon.Experimental
XipamideThe risk or severity of adverse effects can be increased when Fentanyl is combined with Xipamide.Experimental
XylazineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Xylazine.Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Fentanyl is combined with Zaleplon.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Fentanyl is combined with Ziconotide.Approved
ZidovudineThe serum concentration of Zidovudine can be increased when it is combined with Fentanyl.Approved
ZimelidineFentanyl may increase the serotonergic activities of Zimelidine.Withdrawn
ZiprasidoneThe serum concentration of Fentanyl can be increased when it is combined with Ziprasidone.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Fentanyl is combined with Zolazepam.Vet Approved
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Fentanyl.Approved, Investigational
ZolpidemFentanyl may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Fentanyl is combined with Zonisamide.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Fentanyl is combined with Zopiclone.Approved
ZotepineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Zotepine.Approved
ZuclopenthixolThe risk or severity of adverse effects can be increased when Fentanyl is combined with Zuclopenthixol.Approved, Investigational
Food Interactions
  • Avoid alcohol.

References

Synthesis Reference

Mark Rubino, "Process of making fentanyl intermediates." U.S. Patent US20060100438, issued May 11, 2006.

US20060100438
General References
  1. Van Bever WF, Niemegeers CJ, Janssen PA: Synthetic analgesics. Synthesis and pharmacology of the diastereoisomers of N-(3-methyl-1-(2-phenylethyl)-4-piperidyl)-N-phenylpropanamide and N-(3-methyl-1-(1-methyl-2-phenylethyl)-4-piperidyl)-N-phenylpropanamide. J Med Chem. 1974 Oct;17(10):1047-51. [PubMed:4420811]
  2. Messina J, Darwish M, Fine PG: Fentanyl buccal tablet. Drugs Today (Barc). 2008 Jan;44(1):41-54. doi: 10.1358/dot.2008.44.1.1178469. [PubMed:18301803]
  3. Taylor DR: Fentanyl buccal tablet: rapid relief from breakthrough pain. Expert Opin Pharmacother. 2007 Dec;8(17):3043-51. [PubMed:18001263]
  4. Simpson DM, Messina J, Xie F, Hale M: Fentanyl buccal tablet for the relief of breakthrough pain in opioid-tolerant adult patients with chronic neuropathic pain: a multicenter, randomized, double-blind, placebo-controlled study. Clin Ther. 2007 Apr;29(4):588-601. [PubMed:17617282]
External Links
Human Metabolome Database
HMDB14951
KEGG Drug
D00320
PubChem Compound
3345
PubChem Substance
46506372
ChemSpider
3228
BindingDB
50008984
ChEBI
119915
ChEMBL
CHEMBL596
Therapeutic Targets Database
DAP000072
PharmGKB
PA449599
IUPHAR
1626
Guide to Pharmacology
GtP Drug Page
HET
7V7
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Fentanyl
ATC Codes
N01AH51 — Fentanyl, combinationsN01AH01 — FentanylN02AB03 — Fentanyl
AHFS Codes
  • 28:24.92 — Miscellaneous Anxiolytics Sedatives and Hypnotics
  • 28:08.08 — Opiate Agonists
PDB Entries
5tzo
FDA label
Download (507 KB)
MSDS
Download (75.5 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0CompletedTreatmentDyspnea1
0Not Yet RecruitingTreatmentEmergence Agitation / Pain1
0RecruitingTreatmentLumbar Spinal Instability / Lumbar Spine Degeneration / Spinal Stenosis of Lumbar Region1
1Active Not RecruitingNot AvailableAAT Deficiency / AATD / Alpha-1 Antitrypsin Deficiency / Fibrosis, Liver1
1CompletedNot AvailableHealthy Volunteers4
1CompletedNot AvailablePostoperative pain1
1CompletedBasic SciencePharmacokinetics and Pharmacodynamics1
1CompletedBasic SciencePharmacology1
1CompletedOtherHealthy Volunteers1
1CompletedSupportive CareOther Acute Pain / Pain Experienced During Cystoscopy1
1CompletedTreatmentBreakthrough Pain1
1CompletedTreatmentHealthy Volunteers3
1CompletedTreatmentOpiate Addiction1
1CompletedTreatmentPain4
1RecruitingTreatmentHead and Neck Carcinoma / Oral Mucositis1
1TerminatedBasic ScienceImmunologic Activity Alteration / Immunologic Activity Alteration [PE] / Pro-inflammatory Activity1
1Unknown StatusTreatmentObstructive Sleep Apnea of Adult1
1, 2Active Not RecruitingTreatmentCesarean Section / Lumbar epidural anesthesia therapy1
1, 2CompletedPreventionPost Operative Pain2
1, 2CompletedSupportive CareAdvanced Cancers / Dyspnea1
1, 2CompletedTreatmentCancers / Pain, Chronic1
1, 2CompletedTreatmentPain, Fracture, Sprain1
1, 2CompletedTreatmentRadical Mastectomy1
1, 2RecruitingTreatmentPain, Acute1
2Active Not RecruitingTreatmentAdvanced Cancers1
2CompletedPreventionAdverse Anesthesia Outcome1
2CompletedSupportive CareChildren1
2CompletedTreatmentAnaesthesia therapy1
2CompletedTreatmentBreakthrough Pain / Cancers1
2CompletedTreatmentCancers / Pain2
2CompletedTreatmentCancers / Pain / Severe Burns / Sickle Cell Disorders1
2CompletedTreatmentCongestive Heart Failure (CHF) / Dyspnea1
2CompletedTreatmentHeroin Dependence / Opioid-Related Disorders / Substance-Related Disorders1
2CompletedTreatmentIrritable Bowel Syndrome (IBS)1
2CompletedTreatmentPain2
2CompletedTreatmentPain, Chronic1
2CompletedTreatmentPain, Intractable1
2CompletedTreatmentAdjunct to general anesthesia therapy1
2Not Yet RecruitingTreatmentDelirium1
2Not Yet RecruitingTreatmentPain, Acute1
2RecruitingSupportive CareBone Metastases1
2RecruitingSupportive CareCancer of Breast / Cancer, Breast / Malignant Neoplasm of Female Breast1
2RecruitingTreatmentBloodpressure / Heart Rate1
2RecruitingTreatmentFractures, Bone1
2RecruitingTreatmentIntrathecal Dexmedetomidine / Pediatric Cancer Surgery1
2Unknown StatusSupportive CareIntracranial Hemorrhages / Ischemia, Brain / Strokes / Vasospasm, Intracranial1
2WithdrawnSupportive CareTraumatic Brain Injury (TBI)1
2WithdrawnTreatmentHb-SS Disease With Vasoocclusive Pain / Hemoglobin SS Disease With Crisis / Hemoglobin SS Disease With Vasoocclusive Crisis / Other Sickle Cell Disease With Vaso-Occlusive Pain / Sickle Cell Disorders1
2, 3CompletedPreventionHypospadias1
2, 3CompletedPreventionPain1
2, 3CompletedTreatmentAnaesthesia therapy1
2, 3CompletedTreatmentChronic Otitis Media1
2, 3CompletedTreatmentConscious Sedation During Procedure / Endobronchial Ultrasound1
2, 3CompletedTreatmentIntracranial Surgery1
2, 3CompletedTreatmentSedation therapy1
2, 3Not Yet RecruitingTreatmentAnalgesia, Obstetrical / Obstetrical Anesthesia / Postpartum Depression1
2, 3Not Yet RecruitingTreatmentArterial Hypotension1
2, 3RecruitingOtherLow Dose of Pethidine for Subarachnoid Anesthesia1
2, 3RecruitingTreatmentAsthma Bronchial / Bronchospasm / Critical Illness1
2, 3RecruitingTreatmentPain Due to Certain Specified Procedures1
2, 3TerminatedSupportive CareDecrease Labor Pain1
2, 3Unknown StatusSupportive CareStillborn Caesarean Section1
3Active Not RecruitingTreatmentPain / Traumatic Limb Injury1
3CompletedNot AvailablePain1
3CompletedDiagnosticCancer, Breast1
3CompletedPreventionObstructive Sleep Apnea (OSA)1
3CompletedPreventionPost-operative Pain for Total Knee Arthroplasty1
3CompletedSupportive CareCancers, Pain2
3CompletedSupportive CarePain1
3CompletedSupportive CarePain, Cancer2
3CompletedSupportive CarePostoperative pain1
3CompletedTreatmentAbscesses / Pain1
3CompletedTreatmentAnaesthesia therapy1
3CompletedTreatmentAnaesthesia therapy / Craniotomy / Neurosurgery1
3CompletedTreatmentAnalgesia / Neonatal Infections / Pain1
3CompletedTreatmentAnesthetic, Sedative and Analgesic Complications in Labor or Delivery / Anesthetic, Sedative or Analgesic Complications in Labor or Delivery1
3CompletedTreatmentBreak Through Pain / Cancers1
3CompletedTreatmentBreakthrough Pain1
3CompletedTreatmentBreakthrough Pain / Cancers1
3CompletedTreatmentCancer Related Pain (Breakthrough Pain)1
3CompletedTreatmentCancers2
3CompletedTreatmentCancers / Pain2
3CompletedTreatmentComplex Regional Pain Syndromes (CRPS) / Postherpetic Neuralgia / Postoperative pain1
3CompletedTreatmentCongenital Cystic Adenomatoid Malformation (CCAM)1
3CompletedTreatmentInfant, Premature, Diseases / Pain / Respiration; Insufficient or Poor, Newborn1
3CompletedTreatmentLow Back Pain (LBP) / Pain, Chronic / Synovitis of osteoarthritis1
3CompletedTreatmentPain3
3CompletedTreatmentPain, Cancer1
3CompletedTreatmentPain, Chronic3
3CompletedTreatmentPain, Intractable1
3CompletedTreatmentPostoperative pain2
3CompletedTreatmentSedation therapy1
3CompletedTreatmentStandard Opioid Analgesic Treatment of Cancer-related Chronic Pain1
3CompletedTreatmentVentilations, Mechanical1
3Not Yet RecruitingPreventionAdjunct to general anesthesia therapy / Anaesthesia therapy / Analgesics / Analgesics, Opioid / Dexmedetomidine / Gabapentin / Ketamine / Lidocaine / Narcotics / Obstructive Sleep Apnea of Child / Oximetry, Pulse / Pathologic Processes / Physiologic Effects of Drugs / Postoperative Complications / Respiratory Depression / Sleep Disordered Breathing (SDB) / Tonsillectomy1
3Not Yet RecruitingTreatmentAcute Appendicitis / Inguinal Hernias1
3Not Yet RecruitingTreatmentArterial Occlusive Diseases1
3Not Yet RecruitingTreatmentPain, Acute1
3Not Yet RecruitingTreatmentPain, Chronic1
3RecruitingSupportive CareMalignant Head and Neck Neoplasm / Mucositis / Radiation-Induced Disorder1
3RecruitingSupportive CarePreoperative Sedation1
3RecruitingTreatmentBMI >30 kg/m21
3RecruitingTreatmentCancers / Pain1
3RecruitingTreatmentIdiopathic Pulmonary Fibrosis (IPF)1
3RecruitingTreatmentInhalation of Nitrous Oxide / Opioid Analgesic Adverse Reaction / Pain1
3TerminatedPreventionTransient Neurologic Syndrome1
3TerminatedTreatmentAnalgesia, Postoperative / Opioid Free Anaesthesia1
3TerminatedTreatmentBone Marrow Diseases / Pain1
3TerminatedTreatmentBreakthrough Pain / Pain / Pain, Chronic1
3TerminatedTreatmentCancers / Pain1
3Unknown StatusSupportive CareCancers / Pain1
3Unknown StatusTreatmentIntubation Complications1
3Unknown StatusTreatmentObesity, Morbid1
3WithdrawnTreatmentLabour Pain1
3WithdrawnTreatmentPain / Palliative Care1
4Active Not RecruitingPreventionHeart Diseases / Hyperglycemias1
4Active Not RecruitingTreatmentAcute Lung Injury (ALI) / Acute Respiratory Distress Syndrome (ARDS) / Critical Illness / Sleep1
4Active Not RecruitingTreatmentSupracondylar Fractures1
4CompletedNot AvailableDigestive System Diseases / Disorientation1
4CompletedNot AvailableFailed Moderate Sedation During Procedure1
4CompletedNot AvailableHealthy Volunteers1
4CompletedNot AvailableLow Back Pain (LBP)2
4CompletedBasic ScienceAnalgesic Drugs / Antinociceptive Agents1
4CompletedDiagnosticPain1
4CompletedDiagnosticToothache1
4CompletedHealth Services ResearchAmputation Stumps1
4CompletedHealth Services ResearchColon Cancer, Rectal Cancer1
4CompletedHealth Services ResearchPostoperative pain1
4CompletedPreventionAmbulatory Surgery / Coughing1
4CompletedPreventionCognitive Impairments1
4CompletedPreventionCritical Illness / Pain1
4CompletedPreventionFentanyl / Pain, Chronic / Remifentanil / Sternotomy1
4CompletedPreventionIntubation, Endotracheal1
4CompletedPreventionPain, Chronic / Postoperative pain1
4CompletedScreeningPatients Undergoing Major Abdominal Surgery / Postoperative Confusion1
4CompletedSupportive CareAdministration Site Reaction1
4CompletedSupportive CareAnesthesia; Reaction1
4CompletedSupportive CareCongenital Muscular Torticollis1
4CompletedSupportive CareHypothermia1
4CompletedSupportive CareHysterectomy (MeSH nr: E04.950.300.399)1
4CompletedSupportive CareLumbar Spine Disc Herniation1
4CompletedSupportive CareNeoplasms, Thyroid1
4CompletedSupportive CarePain1
4CompletedTreatmentAbscesses / Pain1
4CompletedTreatmentAnalgesia1
4CompletedTreatmentAnalgesia, Patient-Controlled / Pain / Postoperative pain1
4CompletedTreatmentArthritis / Rheumatoid Arthritis / Synovitis of osteoarthritis1
4CompletedTreatmentArthritis / Synovitis of osteoarthritis1
4CompletedTreatmentCancer of Head and Neck / Pain1
4CompletedTreatmentCancers / Pain, Cancer1
4CompletedTreatmentColonoscopy / Sedation, Conscious1
4CompletedTreatmentConscious Sedation Failure During Procedure1
4CompletedTreatmentCurettage / Pregnancy termination therapy1
4CompletedTreatmentDexmedetomidine in Subarachnoidal Anesthesia1
4CompletedTreatmentEndoscopic Retrograde Cholangiopancreatography1
4CompletedTreatmentEndoscopy1
4CompletedTreatmentEndoscopy / Inflammatory Bowel Diseases (IBD) / Sedation therapy1
4CompletedTreatmentFailed Moderate Sedation During Procedure1
4CompletedTreatmentCaudal epidural block therapy / Forearm Injuries / Orthopedic Procedures / Traumas / Upper Extremity1
4CompletedTreatmentGall Stone Disease1
4CompletedTreatmentHemodynamic Response / Skull Pins Application1
4CompletedTreatmentInadequate or Impaired Respiratory Function / Pain1
4CompletedTreatmentIntubations / Newborns / Preterms1
4CompletedTreatmentLabour Pain1
4CompletedTreatmentLow Back Pain (LBP) / Synovitis of osteoarthritis1
4CompletedTreatmentLung Function1
4CompletedTreatmentComputerized tomography / MRI of liver / Ultrasound1
4CompletedTreatmentMigraine Disorders1
4CompletedTreatmentMinor Procedural Pain1
4CompletedTreatmentOocyte Retrieval / Postoperative pain1
4CompletedTreatmentNeurocostal neuralgia / Opioid-Related Disorders1
4CompletedTreatmentCaudal epidural block therapy / Orthopedic Procedures / Shoulder1
4CompletedTreatmentOsteoarthritis of the Knees2
4CompletedTreatmentOtitis1
4CompletedTreatmentOtitis Media (OM)1
4CompletedTreatmentPain3
4CompletedTreatmentPain, Chronic2
4CompletedTreatmentPain, Chronic / Postoperative pain1
4CompletedTreatmentPain / Quality of Life1
4CompletedTreatmentPain / Sickle Cell Disorders1
4CompletedTreatmentPost-Operative Pain1
4CompletedTreatmentPostoperative Pain After Breast Reconstruction With Abdominal Flap1
4CompletedTreatmentPostoperative pain4
4CompletedTreatmentSedation therapy2
4CompletedTreatmentSepsis / Shock, Septic / Systemic Inflammatory Response Syndrome (SIRS)1
4CompletedTreatmentTonsillitis1
4CompletedTreatmentTotal Knee Arthroplasty (TKA)1
4Enrolling by InvitationSupportive CareSmooth muscle relaxation prior to radiological procedures1
4Enrolling by InvitationTreatmentAnesthesia Complication / Hemodynamics Instability / Ileus paralytic / Nausea / Postoperative pain / Vomiting1
4Enrolling by InvitationTreatmentComplications / Delirium / Ventilations, Mechanical1
4Not Yet RecruitingNot AvailableAdverse Reaction to Spinal Anesthetic / Maternal Care for Cervical Incompetence1
4Not Yet RecruitingPreventionC.Surgical Procedure; Cardiac / Delirium1
4Not Yet RecruitingSupportive CareInfertilities1
4Not Yet RecruitingTreatmentAnalgesics, Opioid / Anti-Inflammatory Agents, Non-Steroidal / Child/Adolescent Problems / Emergency Service, Hospital / Fentanyl / Ibuprofen / Pain, Acute1
4Not Yet RecruitingTreatmentHeadaches1
4Not Yet RecruitingTreatmentInfertility, Female / Postoperative pain1
4Not Yet RecruitingTreatmentKnee Replacement, Total1
4Not Yet RecruitingTreatmentPain, Acute / Posttraumatic Stress Disorders / Wound Care1
4Not Yet RecruitingTreatmentShock, Septic1
4RecruitingDiagnosticLiver Diseases1
4RecruitingHealth Services ResearchMalignant Neoplasm of Female Breast1
4RecruitingOtherPeer Review, Research1
4RecruitingPreventionAnaesthesia therapy / Hip Fractures1
4RecruitingPreventionLabour Pain1
4RecruitingPreventionSleep Apnea Syndromes / Sleep Apnea, Obstructive1
4RecruitingPreventionSurgery, Laparoscopic1
4RecruitingSupportive CareBreakthrough Pain / Gastrostomy / Neoplasms, Upper Aerodigestive Tract1
4RecruitingSupportive CareColon Diverticulosis / Colonic Neoplasms / Constipation Drug Induced / Diverticulitis, Colonic / Ileus / Ileus paralytic / Ileus; Mechanical / Malignant Neoplasm of Colon / Occasional Constipation / Postoperative pain / Rectum Cancer / Rectum Neoplasm1
4RecruitingSupportive CareCritical Care / Intensive Care / Multiple Organ Failure1
4RecruitingSupportive CareLabour Pain1
4RecruitingTreatmentAcute Agitation / Respiratory Failure / Sepsis1
4RecruitingTreatmentAcute Pain Due to Trauma2
4RecruitingTreatmentAnaesthesia therapy / Delirium / Hip Fractures1
4RecruitingTreatmentBladder Tumors / Postoperative Cognitive Dysfunction1
4RecruitingTreatmentBreakthrough Pain / Pain, Chronic / Pain, Intractable1
4RecruitingTreatmentColonoscopy / Pain1
4RecruitingTreatmentComplications; Cesarean Section1
4RecruitingTreatmentCoronary Artery Disease1
4RecruitingTreatmentDexmedetomidine / Mechanically Ventilated Sedated Patients / Midazolam / Sedation therapy / Ventilations, Mechanical1
4RecruitingTreatmentLabour Pain1
4RecruitingTreatmentOtitis Media (OM) / Postoperative pain1
4RecruitingTreatmentPain4
4RecruitingTreatmentPain, Acute1
4RecruitingTreatmentPectus Excavatum1
4RecruitingTreatmentPost-operative Residual Curarization1
4RecruitingTreatmentPostoperative pain3
4RecruitingTreatmentTerminal Cancer1
4SuspendedTreatmentPain, Chronic1
4TerminatedNot AvailableBreakthrough Pain / Pain, Cancer1
4TerminatedTreatmentOrthopedic Procedures / Procedural Sedation / Regional Anesthesia Block1
4TerminatedTreatmentPain3
4TerminatedTreatmentPostoperative pain2
4Unknown StatusDiagnosticSafety of Gastroscopy1
4Unknown StatusPreventionDelirium1
4Unknown StatusPreventionSedative Withdrawal Delirium1
4Unknown StatusTreatmentAnaesthesia therapy / Hemodynamics / Oxidative Stress1
4Unknown StatusTreatmentCesarean Section / Local Anaesthetics Causing Adverse Effects in Therapeutic Use / Spinal Anaesthesia1
4Unknown StatusTreatmentCritical Illness / Ventilations, Mechanical1
4Unknown StatusTreatmentDelirium1
4Unknown StatusTreatmentEmergency1
4Unknown StatusTreatmentEpidural Block / Labour / Pregnancy / Primigravida Labour1
4Unknown StatusTreatmentFailed Conscious Sedation During Procedure1
4Unknown StatusTreatmentLabour Pain1
4Unknown StatusTreatmentLiver Cirrhosis1
4Unknown StatusTreatmentMechanical Ventilation Complication1
4Unknown StatusTreatmentPain / Traumas1
4Unknown StatusTreatmentSafety of Dexmedetomidine Sedation1
4Unknown StatusTreatmentAdjunct to general anesthesia therapy1
4WithdrawnSupportive CarePain1
4WithdrawnTreatmentAbscesses1
4WithdrawnTreatmentPostoperative pain1
4WithdrawnTreatmentSleep1
Not AvailableActive Not RecruitingPreventionCancer, Breast / Postoperative pain / Prophylaxis against postoperative nausea and vomiting1
Not AvailableActive Not RecruitingTreatmentPain1
Not AvailableActive Not RecruitingTreatmentPain, Chronic1
Not AvailableCompletedNot AvailableAdequate Anesthesia With Unimpaired Motor Strength1
Not AvailableCompletedNot AvailableAnaesthesia therapy / Maternal Hypotension1
Not AvailableCompletedNot AvailableBreakthrough Cancer Pain / Pain, Cancer / Pain, Neuropathic / Tumors1
Not AvailableCompletedNot AvailableBreakthrough Cancer Pain / Quality of Life1
Not AvailableCompletedNot AvailableBreakthrough Pain / Cancers1
Not AvailableCompletedNot AvailableCancer, Ovarian / Cervical Cancers / Endometrial Cancers / Fallopian Tube Cancer / Pain / Perioperative/Postoperative Complications / Sarcomas1
Not AvailableCompletedNot AvailableCancers / Pain1
Not AvailableCompletedNot AvailableChronic Obstructive Pulmonary Disease (COPD)1
Not AvailableCompletedNot AvailableHorner's Syndrome1
Not AvailableCompletedNot AvailableLabour Pain1
Not AvailableCompletedNot AvailableObstructive Sleep Apnea (OSA)1
Not AvailableCompletedNot AvailablePain1
Not AvailableCompletedNot AvailableRenal Failure1
Not AvailableCompletedNot AvailableSevere Chronic Pain1
Not AvailableCompletedBasic ScienceBioavailability1
Not AvailableCompletedDiagnosticHealthy Volunteers1
Not AvailableCompletedDiagnosticSacroiliac Joint Pain / Sympathetically Maintained Pain1
Not AvailableCompletedPreventionAcute Agitation1
Not AvailableCompletedPreventionAmputation Stumps1
Not AvailableCompletedPreventionAnesthesia Emergence Delirium1
Not AvailableCompletedPreventionCesarean Section1
Not AvailableCompletedPreventionCoughing Responses at Tracheal Extubation1
Not AvailableCompletedPreventionDonor Hepatectomy1
Not AvailableCompletedPreventionEmergence Delirium1
Not AvailableCompletedPreventionGeneral Surgery1
Not AvailableCompletedPreventionGeneral Surgery / Prostate Cancer1
Not AvailableCompletedPreventionPain1
Not AvailableCompletedPreventionPostoperative pain1
Not AvailableCompletedSupportive CareAnesthesia Intubation Complications1
Not AvailableCompletedSupportive CarePain1
Not AvailableCompletedSupportive CareRespiratory Failure1
Not AvailableCompletedSupportive CareUreteroneocystostomy1
Not AvailableCompletedTreatmentAcute Renal Colic1
Not AvailableCompletedTreatmentAnaesthesia therapy1
Not AvailableCompletedTreatmentAnaesthesia therapy / Immunotoxicity / Inert Gas Narcosis1
Not AvailableCompletedTreatmentAnalgesia, Postoperative2
Not AvailableCompletedTreatmentAtrioventricular Septal Defects / Tetralogy Of Fallot / Ventricular Septal Defects1
Not AvailableCompletedTreatmentBPH( Benign Prostate Hyperplasia) / TURP(Transurethral Resection of Prostate)1
Not AvailableCompletedTreatmentCesarean Delivery1
Not AvailableCompletedTreatmentChronic Obstructive Pulmonary Disease (COPD)1
Not AvailableCompletedTreatmentComplex Regional Pain Syndromes (CRPS) / Peripheral Neuropathy / Peripheral Neuropathy, CRPS1 and Postamputation Pain1
Not AvailableCompletedTreatmentComplication of Gastrostomy1
Not AvailableCompletedTreatmentCongenital Skelectal Anomaly1
Not AvailableCompletedTreatmentFemoral Fractures1
Not AvailableCompletedTreatmentFentanyl Analgesia1
Not AvailableCompletedTreatmentFracture Bone / Pain1
Not AvailableCompletedTreatmentHip Fractures1
Not AvailableCompletedTreatmentKnee Replacement Surgery / Primary Knee Arthroplasty1
Not AvailableCompletedTreatmentLabour Pain3
Not AvailableCompletedTreatmentAdjunct to general anesthesia therapy / Laparoscopic Cholecystectomy1
Not AvailableCompletedTreatmentLiving Donor Liver Transplantation1
Not AvailableCompletedTreatmentOpen Heart Surgery / Postoperative pain1
Not AvailableCompletedTreatmentOpioid Consumption / Postoperative pain1
Not AvailableCompletedTreatmentOsteoarthritis of the Knees / Osteoarthritis, Hip / Osteoarthritis, Shoulder1
Not AvailableCompletedTreatmentPain1
Not AvailableCompletedTreatmentPain, Chronic1
Not AvailableCompletedTreatmentPain / Perioperative/Postoperative Complications1
Not AvailableCompletedTreatmentPostoperative pain1
Not AvailableCompletedTreatmentProstate Cancer1
Not AvailableCompletedTreatmentRespiration Disorders1
Not AvailableEnrolling by InvitationPreventionPostoperative Delirium1
Not AvailableNot Yet RecruitingPreventionHeart Rate / Mean Arterial Pressure1
Not AvailableNot Yet RecruitingPreventionCaudal epidural block therapy / Postoperative pain / Surgery, Cardiac1
Not AvailableNot Yet RecruitingSupportive CareFemale Breast Cancer1
Not AvailableNot Yet RecruitingTreatmentAcute Myocardial Infarction (AMI)1
Not AvailableNot Yet RecruitingTreatmentAnaesthesia therapy / Cancers / Pain1
Not AvailableNot Yet RecruitingTreatmentColonic Neoplasms1
Not AvailableNot Yet RecruitingTreatmentLabour Analgesia1
Not AvailableNot Yet RecruitingTreatmentObesity, Morbid1
Not AvailableNot Yet RecruitingTreatmentPain Uterus1
Not AvailableNot Yet RecruitingTreatmentPostoperative Recovery / Transurethral Resection of the Bladder / Urinary Bladder Neoplasms1
Not AvailableNot Yet RecruitingTreatmentSedation therapy1
Not AvailableRecruitingNot AvailablePain1
Not AvailableRecruitingNot AvailablePharmacogenetic and Duration of Labor Fentanyl Analgesia1
Not AvailableRecruitingNot AvailableRenal Failure1
Not AvailableRecruitingBasic ScienceHeart Failure, Unspecified1
Not AvailableRecruitingDiagnosticVentricular Tachycardia (VT)1
Not AvailableRecruitingHealth Services ResearchOpioid Free Anaesthesia1
Not AvailableRecruitingPreventionIntubation; Difficult or Failed1
Not AvailableRecruitingPreventionLabour Pain / Postpartum Depression1
Not AvailableRecruitingPreventionPregnancy1
Not AvailableRecruitingPreventionProphylaxis against postoperative nausea and vomiting1
Not AvailableRecruitingSupportive CareRadical Cystectomy1
Not AvailableRecruitingTreatmentAcute Respiratory Failure1
Not AvailableRecruitingTreatmentAnaesthesia therapy / General Surgery / Pain1
Not AvailableRecruitingTreatmentColonoscopy1
Not AvailableRecruitingTreatmentNausea / Pain1
Not AvailableRecruitingTreatmentOpioid Use, Unspecified1
Not AvailableRecruitingTreatmentPost Laparotomy Pain Treatment1
Not AvailableRecruitingTreatmentPostoperative Pain Control / Wrist Injury1
Not AvailableRecruitingTreatmentPostoperative pain1
Not AvailableRecruitingTreatmentPregnancy1
Not AvailableRecruitingTreatmentRupture of Anterior Cruciate Ligament / Tear of Anterior Cruciate Ligament1
Not AvailableRecruitingTreatmentSpinal Anaesthesia1
Not AvailableRecruitingTreatmentThe Comparison of the I-gel and Endotracheal Tube About in Different Ventilation Settings During Laparoscopic Surgery1
Not AvailableSuspendedSupportive CareNeoplasms, Malignant1
Not AvailableTerminatedNot AvailableBrain and Central Nervous System Tumors / Chronic Myeloproliferative Disorders / Leukemias / Lymphoproliferative Disorders / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Neoplasms / Pain / Precancerous Conditions / Unspecified Adult Solid Tumor, Protocol Specific1
Not AvailableTerminatedNot AvailableComplications; Cesarean Section / Effects of; Anesthesia, Spinal and Epidural, in Pregnancy / Hemodynamics Instability / Personal Satisfaction1
Not AvailableTerminatedTreatmentAdvanced Cancers / Malignant Pleural Effusions1
Not AvailableTerminatedTreatmentBMI >30 kg/m2 / Sleep Apnea, Obstructive1
Not AvailableTerminatedTreatmentPain1
Not AvailableTerminatedTreatmentPostoperative pain / Shoulder Pain1
Not AvailableTerminatedTreatmentProcedural Sedation / Procedural Sedation and Analgesia1
Not AvailableTerminatedTreatmentRespiratory Failure1
Not AvailableUnknown StatusNot AvailableNausea / Vomiting1
Not AvailableUnknown StatusSupportive CareBishop Score / Cervical Dilatation / Duration of Delivery1
Not AvailableUnknown StatusSupportive CareDiverticulosis, Colonic / Malignant Neoplasm of Colon / Rectal Carcinoma1
Not AvailableUnknown StatusSupportive CareAdjunct to general anesthesia therapy1
Not AvailableUnknown StatusTreatmentAnalgesia1
Not AvailableUnknown StatusTreatmentLiver Diseases1
Not AvailableUnknown StatusTreatmentOpioid Dependence1
Not AvailableUnknown StatusTreatmentPain1
Not AvailableWithdrawnPreventionRespiratory Complications / Swallowing Disorders1
Not AvailableWithdrawnPreventionVaginal Delivery1
Not AvailableWithdrawnSupportive CarePain / Traumas1
Not AvailableWithdrawnTreatmentFull Term Pregnant Patients / Undergoing Lower Segment Caesarian Section1

Pharmacoeconomics

Manufacturers
  • Ortho mcneil janssen pharmaceuticals inc
  • Actavis southatlantic llc
  • Lavipharm laboratories inc
  • Mylan technologies inc
  • Noven pharmaceuticals inc
  • Teva pharmaceuticals usa
  • Watson laboratories inc
  • Meda pharmaceuticals inc
  • Abbott laboratories hosp products div
  • Hospira inc
  • Baxter healthcare corp anesthesia and critical care
  • Marsam pharmaceuticals llc
  • Akorn inc
  • Cephalon inc
  • Barr laboratories inc
  • Mallinckrodt inc
  • Incline therapeutics inc
  • Abbott laboratories
Packagers
Dosage forms
FormRouteStrength
TabletSublingual100 ug/1
TabletSublingual100 mcg
TabletSublingual200 mcg
TabletSublingual200 ug/1
TabletSublingual300 mcg
TabletSublingual300 ug/1
TabletSublingual400 mcg
TabletSublingual400 ug/1
TabletSublingual600 mcg
TabletSublingual600 ug/1
TabletSublingual800 mcg
TabletSublingual800 ug/1
Tablet, orally disintegratingSublingual100 ug/1
Tablet, orally disintegratingSublingual200 ug/1
Tablet, orally disintegratingSublingual300 ug/1
Tablet, orally disintegratingSublingual400 ug/1
Tablet, orally disintegratingSublingual600 ug/1
Tablet, orally disintegratingSublingual800 ug/1
PatchTransdermal12.5 ug/h
TabletBuccal100 micrograms
TabletBuccal200 micrograms
TabletBuccal400 micrograms
TabletBuccal600 micrograms
TabletBuccal800 micrograms
PatchTransdermal1.28 mg/[USP'U]
PatchTransdermal10.2 mg/[USP'U]
PatchTransdermal100 ug/h
PatchTransdermal12 ug/h
PatchTransdermal12 ug/1
PatchTransdermal2.55 mg/[USP'U]
PatchTransdermal25 ug/h
PatchTransdermal37.5 ug/h
PatchTransdermal5.1 mg/[USP'U]
PatchTransdermal50 ug/h
PatchTransdermal62.5 ug/h
PatchTransdermal7.65 mg/[USP'U]
PatchTransdermal75 ug/h
PatchTransdermal87.5 ug/h
Patch, extended releaseTransdermal100 ug/h
Patch, extended releaseTransdermal100 ug/72h
Patch, extended releaseTransdermal12 ug/h
Patch, extended releaseTransdermal2.5 mg/72h
Patch, extended releaseTransdermal25 ug/h
Patch, extended releaseTransdermal25 ug/72h
Patch, extended releaseTransdermal5 mg/72h
Patch, extended releaseTransdermal50 ug/72h
Patch, extended releaseTransdermal50 ug/h
Patch, extended releaseTransdermal7.5 mg/72h
Patch, extended releaseTransdermal75 ug/h
TabletBuccal; Oral; Transmucosal100 ug/1
TabletBuccal; Oral; Transmucosal200 ug/1
TabletBuccal; Oral; Transmucosal400 ug/1
TabletBuccal; Oral; Transmucosal600 ug/1
TabletBuccal; Oral; Transmucosal800 ug/1
InjectionIntramuscular; Intravenous50 ug/mL
InjectionIntravenous50 ug/mL
Injection, solutionIntramuscular; Intravenous50 ug/mL
Injection, solutionIntravenous10 ug/mL
Injection, solutionIntravenous20 ug/mL
Injection, solutionIntravenous25 ug/mL
Injection, solutionIntravenous5 ug/mL
Injection, solutionIntravenous50 ug/mL
LozengeOral; Transmucosal1200 ug/1
LozengeOral; Transmucosal1600 ug/1
LozengeOral; Transmucosal200 ug/1
LozengeOral; Transmucosal800 ug/1
LozengeTransmucosal1200 ug/1
LozengeTransmucosal1600 ug/1
LozengeTransmucosal200 ug/1
LozengeTransmucosal400 ug/1
LozengeTransmucosal600 ug/1
LozengeTransmucosal800 ug/1
SolutionEpidural; Intramuscular; Intravenous50 mcg
LiquidEpidural; Intramuscular; Intravenous50 mcg
Injection, solutionEpidural
PatchTransdermal100 ug/1
PatchTransdermal12.5 ug/1
PatchTransdermal25 ug/1
PatchTransdermal50 ug/1
PatchTransdermal75 ug/1
Patch, extended releaseTransdermal12.5 ug/h
Patch, extended releaseTransdermal100 mcg
Patch, extended releaseTransdermal25 mcg
Patch, extended releaseTransdermal50 mcg
Patch, extended releaseTransdermal75 mcg
TabletBuccal; Sublingual100 ug/1
TabletBuccal; Sublingual200 ug/1
TabletBuccal; Sublingual400 ug/1
TabletBuccal; Sublingual600 ug/1
TabletBuccal; Sublingual800 ug/1
Tablet, effervescentBuccal; Sublingual100 mcg
Tablet, effervescentBuccal; Sublingual200 mcg
Tablet, effervescentBuccal; Sublingual400 mcg
Tablet, effervescentBuccal; Sublingual600 mcg
Tablet, effervescentBuccal; Sublingual800 mcg
LiquidIntramuscular; Intravenous
SolutionNasal100 mcg
SolutionNasal200 mcg
SolutionNasal50 mcg
PatchTransdermal40 ug/1
PatchTransdermal40 μg/dose
SprayNasal100 ug/1
SprayNasal300 ug/1
SprayNasal400 ug/1
Film, solubleBuccal1200 mcg
Film, solubleBuccal200 mcg
Film, solubleBuccal400 mcg
Film, solubleBuccal600 mcg
Film, solubleBuccal800 mcg
PatchTransdermal12.0 mcg
PatchTransdermal10 mg
PatchTransdermal2.5 mg
PatchTransdermal5 mg
PatchTransdermal7.5 mg
PatchTransdermal37 mcg
SpraySublingual.1 mg/1
SpraySublingual.2 mg/1
SpraySublingual.4 mg/1
SpraySublingual.6 mg/1
SpraySublingual.8 mg/1
PatchTransdermal100 mcg
PatchTransdermal12 mcg
PatchTransdermal25 mcg
PatchTransdermal50 mcg
PatchTransdermal75 mcg
LozengeOral; Transmucosal1200 1/1
LozengeOral; Transmucosal400 ug/1
LozengeOral; Transmucosal600 ug/1
Prices
Unit descriptionCostUnit
Fentanyl base powder1498.18USD g
Fentanyl citrate powder1062.5USD g
Duragesic-100 5 100 mcg/hr Patches Box411.59USD box
Duragesic-75 5 75 mcg/hr Patches Box318.93USD box
Fentanyl 5 100 mcg/hr Patches Box210.0USD box
Duragesic-50 5 50 mcg/hr Patches Box205.78USD box
Actiq 1600 mcg lozenge150.29USD lozenge
Fentanyl 5 50 mcg/hr Patches Box129.99USD box
Actiq 1200 mcg lozenge121.82USD lozenge
Actiq 1600 mcg Lollipop119.42USD lollipop
Duragesic-25 5 25 mcg/hr Patches Box114.42USD box
Duragesic-12 5 12 mcg/hr Patches Box95.99USD box
Actiq 800 mcg lozenge93.76USD lozenge
Actiq 1200 mcg Lollipop85.7USD lollipop
Duragesic 100 mcg/hr patch81.36USD patch
Actiq 600 mcg lozenge79.16USD lozenge
Actiq 800 mcg Lollipop75.98USD lollipop
Fentanyl 5 12 (12.5)mcg/hr Patches Box67.99USD box
Fentanyl 5 25 mcg/hr Patches Box66.66USD box
Actiq 600 mcg Lollipop65.13USD lollipop
Actiq 400 mcg lozenge64.62USD lozenge
Fentanyl 100 mcg/hr patch61.69USD patch
Duragesic 75 mcg/hr patch61.3USD patch
Fentora 800 mcg buccal tablet54.77USD tablet
Actiq 400 mcg Lollipop53.75USD lollipop
Actiq 200 mcg lozenge51.05USD lozenge
Fentora 600 mcg buccal tablet47.37USD tablet
Fentanyl 75 mcg/hr patch46.48USD patch
Actiq 200 mcg Lollipop42.14USD lollipop
Duragesic 50 mcg/hr patch40.19USD patch
FentaNYL Citrate 1600 mcg Lollipop38.53USD lollipop
Fentora 400 mcg buccal tablet34.24USD tablet
Fentanyl 50 mcg/hr patch30.47USD patch
FentaNYL Citrate 1200 mcg Lollipop30.0USD lollipop
Fentora 300 mcg buccal tablet28.84USD tablet
Fentora 200 mcg buccal tablet23.57USD tablet
Duragesic 25 mcg/hr patch21.98USD patch
FentaNYL Citrate 400 mcg Lollipop20.0USD lollipop
Fentora 100 mcg buccal tablet18.64USD tablet
Duragesic 12 mcg/hr patch18.21USD patch
Fentanyl 25 mcg/hr patch16.67USD patch
Fentanyl 12 mcg/hr patch13.8USD patch
Fentanyl 0.05 mg/ml vial1.96USD ml
Fentanyl cit 1500 mcg/30 ml1.44USD ml
Fentanyl-ns 50 mcg/ml syringe1.0USD ml
Fentanyl-ns 300 mcg/30 ml syr0.99USD ml
Fentanyl-ns 20 mcg/ml syringe0.72USD ml
Fentanyl-ns 10 mcg/ml syringe0.64USD ml
Fentanyl cit 2750 mcg/55 ml0.35USD ml
Fentanyl-ns 500 mcg/50 ml syr0.31USD ml
Sublimaze 0.05 mg/ml ampul0.23USD ml
Fentanyl 0.05 mg/ml ampul0.21USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US6317629No1995-06-022012-06-02Us
US6200604No1999-03-262019-03-26Us
US6974590No1999-03-262019-03-26Us
US8728441No1999-03-262019-03-26Us
US8753611No1999-03-262019-03-26Us
US8765100No1999-03-262019-03-26Us
US7862833No2008-06-152028-06-15Us
US8119158No2004-12-302024-12-30Us
US8092832No2004-12-302024-12-30Us
US7862832No2008-06-152028-06-15Us
US6761910No1999-09-242019-09-24Us
US6195582No1999-01-282019-01-28Us
US6881208No2002-04-192022-04-19Us
US8428709No2012-06-112032-06-11Us
US8428708No2012-05-212032-05-21Us
US6169920No1998-01-022018-01-02Us
US8781571No2012-03-312032-03-31Us
US6181963No1999-11-022019-11-02Us
US5843014No1995-12-012015-12-01Us
US5697896No1996-12-162016-12-16Us
US6975902No2004-04-012024-04-01Us
US8301238No2011-09-302031-09-30Us
US9095706No2013-02-032033-02-03Us
US7579019No2000-01-222020-01-22Us
US6159498No1996-10-182016-10-18Us
US6759059No1999-09-242019-09-24Us
US7910132No1999-09-242019-09-24Us
US8889176No2004-01-162024-01-16Us
US6432440No1998-04-202018-04-20Us
US8216604No2004-10-032024-10-03Us
US9078814No2004-01-082024-01-08Us
US8486973No2010-04-272030-04-27Us
US8835460No2007-01-252027-01-25Us
US8835459No2007-01-252027-01-25Us
US9241935No2007-01-252027-01-25Us
US8486972No2010-04-272030-04-27Us
US9364656No2011-09-302031-09-30Us
US9597288No2007-07-232027-07-23Us
US9642844No2007-01-252027-01-25Us
US9289387No2007-01-252027-01-25Us
US9642797No2007-01-252027-01-25Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)83-84 US. Patent 3,141,823.
water solubility200 mg/L (at 25 °C)ROY,SD & FLYNN,GL (1988)
logP4.05SANGSTER (1993)
Predicted Properties
PropertyValueSource
Water Solubility0.024 mg/mLALOGPS
logP4.12ALOGPS
logP3.82ChemAxon
logS-4.2ALOGPS
pKa (Strongest Basic)8.77ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area23.55 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity103.48 m3·mol-1ChemAxon
Polarizability40.03 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9766
Blood Brain Barrier+0.9901
Caco-2 permeable+0.6459
P-glycoprotein substrateSubstrate0.6082
P-glycoprotein inhibitor IInhibitor0.7161
P-glycoprotein inhibitor IINon-inhibitor0.8371
Renal organic cation transporterInhibitor0.5824
CYP450 2C9 substrateNon-substrate0.7879
CYP450 2D6 substrateNon-substrate0.9117
CYP450 3A4 substrateSubstrate0.5856
CYP450 1A2 substrateNon-inhibitor0.7715
CYP450 2C9 inhibitorNon-inhibitor0.873
CYP450 2D6 inhibitorNon-inhibitor0.6327
CYP450 2C19 inhibitorNon-inhibitor0.5724
CYP450 3A4 inhibitorNon-inhibitor0.8218
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.7346
Ames testNon AMES toxic0.8417
CarcinogenicityNon-carcinogens0.8536
BiodegradationNot ready biodegradable0.8554
Rat acute toxicity3.9836 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.796
hERG inhibition (predictor II)Inhibitor0.6791
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Mass Spectrum (Electron Ionization)MSsplash10-0002-9850000000-7ce3a6f35f5dee98185f
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-000i-0009000000-62593b54c6285a566893
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-000i-0209000000-d550d803c25d31570227
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-000i-0901000000-09bd125eea134f8811a4
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-000i-0900000000-2c34993eade063cb426f
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-001r-0900000000-beb72ea99dc9c125d29b
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-000i-0009000000-bf70e4d857c26d30032f
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-000i-0907000000-a9f5d0c422eff1474d38
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-000i-0900000000-0c03ba9ef576114a9503
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0a4i-0900000000-d2a36b402c3a7424fab6
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0a4i-1900000000-e0cbdfad80c306baabc1
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0a4i-2900000000-ea551550ac6cbe6d3960
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0pdi-8900000000-89b1a77e558ec74cf3ac
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0kdj-9400000000-358833c028a079789d0b
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0ufs-9200000000-ff2c211a084a5f124781

Taxonomy

Description
This compound belongs to the class of organic compounds known as fentanyls. These are compounds containing the fentanyl moiety or a derivative, which is based on a N-(1-(2-phenylethyl)-4-piperidinyl)-N-phenylpropanamide skeleton.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Piperidines
Sub Class
Fentanyls
Direct Parent
Fentanyls
Alternative Parents
Phenethylamines / Anilides / Aralkylamines / Tertiary carboxylic acid amides / Trialkylamines / Amino acids and derivatives / Azacyclic compounds / Organopnictogen compounds / Organic oxides / Hydrocarbon derivatives
show 1 more
Substituents
Fentanyl / Phenethylamine / Anilide / Aralkylamine / Monocyclic benzene moiety / Benzenoid / Tertiary carboxylic acid amide / Amino acid or derivatives / Carboxamide group / Tertiary amine
show 13 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
piperidines, monocarboxylic acid amide, anilide (CHEBI:119915)

Targets

Details
1. Mu-type opioid receptor
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Agonist
General Function
Voltage-gated calcium channel activity
Specific Function
Receptor for endogenous opioids such as beta-endorphin and endomorphin. Receptor for natural and synthetic opioids including morphine, heroin, DAMGO, fentanyl, etorphine, buprenorphin and methadone...
Gene Name
OPRM1
Uniprot ID
P35372
Uniprot Name
Mu-type opioid receptor
Molecular Weight
44778.855 Da
References
  1. You HJ, Colpaert FC, Arendt-Nielsen L: The novel analgesic and high-efficacy 5-HT1A receptor agonist F 13640 inhibits nociceptive responses, wind-up, and after-discharges in spinal neurons and withdrawal reflexes. Exp Neurol. 2005 Jan;191(1):174-83. [PubMed:15589524]
  2. Scott LJ, Perry CM: Remifentanil: a review of its use during the induction and maintenance of general anaesthesia. Drugs. 2005;65(13):1793-823. [PubMed:16114980]
  3. Scott LJ, Perry CM: Spotlight on remifentanil for general anaesthesia. CNS Drugs. 2005;19(12):1069-74. [PubMed:16332149]
  4. Dosen-Micovic L, Ivanovic M, Micovic V: Steric interactions and the activity of fentanyl analogs at the mu-opioid receptor. Bioorg Med Chem. 2006 May 1;14(9):2887-95. Epub 2006 Jan 11. [PubMed:16376082]
  5. Dardonville C, Fernandez-Fernandez C, Gibbons SL, Ryan GJ, Jagerovic N, Gabilondo AM, Meana JJ, Callado LF: Synthesis and pharmacological studies of new hybrid derivatives of fentanyl active at the mu-opioid receptor and I2-imidazoline binding sites. Bioorg Med Chem. 2006 Oct 1;14(19):6570-80. Epub 2006 Jun 23. [PubMed:16797997]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  7. Hajiha M, DuBord MA, Liu H, Horner RL: Opioid receptor mechanisms at the hypoglossal motor pool and effects on tongue muscle activity in vivo. J Physiol. 2009 Jun 1;587(Pt 11):2677-92. doi: 10.1113/jphysiol.2009.171678. Epub 2009 Apr 29. [PubMed:19403616]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Agonist
General Function
Opioid receptor activity
Specific Function
G-protein coupled receptor that functions as receptor for endogenous enkephalins and for a subset of other opioids. Ligand binding causes a conformation change that triggers signaling via guanine n...
Gene Name
OPRD1
Uniprot ID
P41143
Uniprot Name
Delta-type opioid receptor
Molecular Weight
40368.235 Da
References
  1. Rodrigues AR, Castro MS, Francischi JN, Perez AC, Duarte ID: Participation of ATP-sensitive K+ channels in the peripheral antinociceptive effect of fentanyl in rats. Braz J Med Biol Res. 2005 Jan;38(1):91-7. Epub 2005 Jan 18. [PubMed:15665994]
  2. Poonawala T, Levay-Young BK, Hebbel RP, Gupta K: Opioids heal ischemic wounds in the rat. Wound Repair Regen. 2005 Mar-Apr;13(2):165-74. [PubMed:15828941]
  3. Sahin AS, Duman A, Atalik EK, Ogun CO, Sahin TK, Erol A, Ozergin U: The mechanisms of the direct vascular effects of fentanyl on isolated human saphenous veins in vitro. J Cardiothorac Vasc Anesth. 2005 Apr;19(2):197-200. [PubMed:15868528]
  4. Darwish M, Tempero K, Kirby M, Thompson J: Pharmacokinetics and dose proportionality of fentanyl effervescent buccal tablets in healthy volunteers. Clin Pharmacokinet. 2005;44(12):1279-86. [PubMed:16372825]
  5. Darwish M, Kirby M, Robertson P Jr, Tracewell W, Jiang JG: Pharmacokinetic properties of fentanyl effervescent buccal tablets: a phase I, open-label, crossover study of single-dose 100, 200, 400, and 800 microg in healthy adult volunteers. Clin Ther. 2006 May;28(5):707-14. [PubMed:16861092]
  6. Hajiha M, DuBord MA, Liu H, Horner RL: Opioid receptor mechanisms at the hypoglossal motor pool and effects on tongue muscle activity in vivo. J Physiol. 2009 Jun 1;587(Pt 11):2677-92. doi: 10.1113/jphysiol.2009.171678. Epub 2009 Apr 29. [PubMed:19403616]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Agonist
General Function
Opioid receptor activity
Specific Function
G-protein coupled opioid receptor that functions as receptor for endogenous alpha-neoendorphins and dynorphins, but has low affinity for beta-endorphins. Also functions as receptor for various synt...
Gene Name
OPRK1
Uniprot ID
P41145
Uniprot Name
Kappa-type opioid receptor
Molecular Weight
42644.665 Da
References
  1. Pascoe JE, Williams KL, Mukhopadhyay P, Rice KC, Woods JH, Ko MC: Effects of mu, kappa, and delta opioid receptor agonists on the function of hypothalamic-pituitary-adrenal axis in monkeys. Psychoneuroendocrinology. 2008 May;33(4):478-86. doi: 10.1016/j.psyneuen.2008.01.006. Epub 2008 Mar 5. [PubMed:18325678]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  2. Ekins S, Bravi G, Wikel JH, Wrighton SA: Three-dimensional-quantitative structure activity relationship analysis of cytochrome P-450 3A4 substrates. J Pharmacol Exp Ther. 1999 Oct;291(1):424-33. [PubMed:10490933]
  3. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP3A5
Uniprot ID
P20815
Uniprot Name
Cytochrome P450 3A5
Molecular Weight
57108.065 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP3A7
Uniprot ID
P24462
Uniprot Name
Cytochrome P450 3A7
Molecular Weight
57525.03 Da
References
  1. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Xenobiotic-transporting atpase activity
Specific Function
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name
ABCB1
Uniprot ID
P08183
Uniprot Name
Multidrug resistance protein 1
Molecular Weight
141477.255 Da
References
  1. Wandel C, Kim R, Wood M, Wood A: Interaction of morphine, fentanyl, sufentanil, alfentanil, and loperamide with the efflux drug transporter P-glycoprotein. Anesthesiology. 2002 Apr;96(4):913-20. [PubMed:11964599]

Drug created on June 13, 2005 07:24 / Updated on October 21, 2017 19:25